

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Elevated serum alkaline phosphatase as an indicator of bacteremia in haemodialysis outpatients —a multicentre retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058666
Article Type:	Original research
Date Submitted by the Author:	24-Oct-2021
Complete List of Authors:	Katasako, Aya; Iizuka Hospital, Department of Nephrology Sasaki, Sho; Iizuka Hospital, Department of Nephrology; Iizuka Hospital, Clinical Research Support Office Raita, Yoshihiko; Okinawa Chubu Hospital, Department of Nephrology Yamamoto, Shungo; Kyoto University Graduate School of Public Health, Department of Healthcare Epidemiology Nishioka, Ryo; Ishikawa Prefectural Central Hospital, Department of Nephrology and Rheumatology Fujisaki, Kiichiro; Iizuka Hospital, Department of Nephrology Tochitani, Kentaro; Kyoto University Graduate School of Public Health, Department of Healthcare Epidemiology Murakami, Minoru; Saku Central Hospital, Department of Nephrology
Keywords:	INFECTIOUS DISEASES, Nephrology < INTERNAL MEDICINE, Dialysis < NEPHROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

ORIGINAL ARTICLE

**Elevated serum alkaline phosphatase as an indicator of bacteremia in haemodialysis
outpatients —a multicentre retrospective cohort study**

Aya Katasako, MD¹, Sho Sasaki, MD, DrPH^{1,2}, Yoshihiko Raita, MD, MPH, MMSc³,
Shungo Yamamoto, MD, DrPH⁴, Kentaro Tochtani, MD⁴, Minoru Murakami, MD, MPH⁵,
Ryo Nishioka, MD⁶, Kiichiro Fujisaki, MD, PhD¹

¹Department of Nephrology, Iizuka Hospital, Iizuka, Japan, ²Clinical Research Support
Office, Iizuka Hospital, Iizuka, Japan, ³Department of Nephrology, Okinawa Chubu Hospital,
Uruma, Japan. ⁴Department of Healthcare Epidemiology, Kyoto University Graduate School
of Public Health, Kyoto, Japan, ⁵Department of Nephrology, Saku Central Hospital, Nagano,
Japan, ⁶Department of Nephrology and Rheumatology, Ishikawa Prefectural Central Hospital,
Kanazawa, Japan

Correspondence to:

Sho Sasaki, MD, DrPH

Department of Nephrology/Clinical Research Support Office, Iizuka Hospital, Fukuoka,

JAPAN

3-83 Yoshio-machi, Iizuka-city, Fukuoka, 820-8505, JAPAN

E-mail address: sasayan0621@gmail.com

1
2
3
4 **ABSTRACT (298 words)**
5

6
7 **Objectives:** Elevated baseline serum alkaline phosphatase (ALP) may correlate with higher
8
9
10
11 medium- to long-term mortality in the general population and in chronic kidney disease
12
13
14 (CKD) patients. There are few data on the association between serum ALP and the short-term
15
16
17 prognosis of patients on haemodialysis (HD). We verified the association of ALP levels and
18
19
20 bacteremia or death in maintenance HD patients suspected of bacteremia in an outpatient
21
22
23 setting.
24
25

26
27 **Setting:** This study involved 315 consecutive HD patients suspected of having bacteremia
28
29
30 with two sets of blood cultures drawn upon admission to either of two tertiary-care university
31
32
33 medical centres from January 2013 to December 2015.
34
35

36
37 **Participants:** We enrolled consecutive cases on maintenance HD who were of age ≥ 18
38
39
40 years. Cases of hospitalised patients who had been transferred from another hospital, who had
41
42
43 a vintage of dialysis < 2 months, who were also undergoing peritoneal dialysis (PD), and who
44
45
46 were receiving HD less than once a week were excluded.
47
48

49
50
51 **Primary and secondary outcome measures:** The primary outcome measure was
52
53
54 bacteraemia and the secondary outcome was in-hospital death.
55
56
57
58
59
60

1
2
3
4 **Results:** After the sampling, 315 cases that met the eligibility criteria were included in the
5
6
7 study. The high-ALP group had a higher incidence of bacteremia. In multivariate analysis,
8
9
10 there was a statistically significant association between higher ALP in hospital visit and
11
12
13 bacteremia (OR: 2.37, 95%CI: 1.17 to 4.83, p=0.02). However, there were no statistically
14
15
16 significant associations between higher ALP and in-hospital death (OR: 1.20, 95%CI: 0.57 to
17
18
19 2.54, p=0.63). A sensitivity analysis of 187 patients with no missing ALP values also
20
21
22 demonstrated a significant association between ALP and bacteremia, but no significant
23
24
25 association between ALP and in-hospital death.
26
27
28

29
30
31 **Conclusions:** Elevated ALP is a predictor of bacteremia. In HD patients suspected of
32
33
34 bacteremia in outpatient settings, increased ALP levels heighten its likelihood.
35
36

37
38 **Trial registration:** none
39
40
41
42
43

44 **Strengths and limitations of this study:**

- 45
46
47 • This is the first multicentre investigation of the association between ALP levels and
48
49
50 bacteremia or death in patients on maintenance HD.
- 51
52
53 • Elevated serum ALP levels in haemodialysis patients suspected of bacteremia could allow
54
55
56 for early recognition and may potentially allow for earlier medical intervention.
57
58
59
60

1
2
3
4 •Our findings should facilitate further research to investigate any causal association of ALP
5
6
7 elevation with bacteremia in complex biological systems.
8

9
10
11 •Although the study sample consisted of patients on maintenance HD from three
12
13
14 geographically diverse hospitals in Japan, our inferences may not be generalisable to patients
15
16
17 on maintenance HD in other clinical settings.
18

19
20
21
22
23
24 **Keywords:** alkaline phosphatase, bacteremia, haemodialysis, mortality, prognostic indicator
25
26
27
28
29

30
31 **(2615 word)**
32

33 **INTRODUCTION**

34
35
36
37 In patients on haemodialysis (HD), it is well known that the second most common cause of
38
39
40 death after cardiovascular events is infection, especially sepsis or bacteremia [1,2]. The
41
42
43 prevalence of bacteremia in patients with HD is 10 to 40 times that in the general population
44
45
46 [3,4] with a 50-fold increase in mortality [5–7].
47
48
49

50
51 Multiple studies have shown a positive relationship between serum alkaline
52
53
54 phosphatase (ALP) and medium- to long-term mortality in the general population and in
55
56
57 chronic kidney disease (CKD) patients, including those on haemodialysis and peritoneal
58
59
60

1
2
3
4 dialysis [8–16]. The explanation is that elevated levels of serum ALP may reflect arterial
5
6
7 stiffness, renal osteodystrophy, and inflammation [11,12,17–19].
8
9

10
11 In addition to the relationship between serum ALP and mid- to long-term prognosis,
12
13
14 observational studies have identified other risk factors for bacteremia in dialysis patients,
15
16
17 including leukocyte dysfunction, malnutrition, parathyroid hormone derangements, and
18
19
20 vitamin D deficiency [8,20–22].
21
22
23

24 We focused on ALP, an enzyme that hydrolyses phosphate monoester. It is a dimer
25
26
27 consisting of two identical molecules, and is expressed as four isoenzymes (placental, germ
28
29
30 cell, intestinal, and tissue-nonspecific [liver/bone/kidney]) [23]. ALP is known as an
31
32
33 indicator of renal osteodystrophy given its close relationship with bone, parathyroid gland
34
35
36 function, the GI tract, and overall mineral balance [24]. Historically, high ALP levels have
37
38
39 been considered related to renal osteodystrophy.
40
41
42
43

44 Damera et al. reported that ALP is one of the inflammatory markers independent of
45
46
47 25-OH vitamin D levels in CKD [25]. In addition, the ‘BAC-HD’ (Body temperature \geq
48
49
50 38.3°C, ALP > 360 U/L, C-reactive protein [CRP] \geq CRP 10 mg/dL, Heart rate \geq 125
51
52
53 beats/min, Drugs: no prior antibiotic use for 1 week) score [26], which we previously
54
55
56
57
58
59
60

1
2
3
4 developed, is a clinical prediction algorithm for bacteremia among patients with HD that
5
6
7 includes ALP levels as scoring factor.
8
9

10
11 Tung et al. showed extremely high ALP levels (ALP > 1000 U/L) to be associated
12
13
14 with bacteremia [27]. However, this study had a very small sample size of 16. In other words,
15
16
17 there are few studies showing an association between serum ALP and short-term prognosis of
18
19
20 bacteraemia and in-hospital mortality.
21
22

23
24 Our aim was to verify the association of ALP levels and bacteremia or death in
25
26
27 maintenance HD patients suspected of bacteremia in an outpatient setting.
28
29
30
31
32
33

34 **METHODS**

35
36
37 This study was approved by the ethics committees of Aso Iizuka Hospital (No. 17167),
38
39
40 Okinawa Chubu Hospital (H28_No. 51), and Saku Central Hospital (201701-01), and was
41
42
43 conducted in accordance with the ethical standards of the Declaration of Helsinki. In the
44
45
46 present study, the Department of Nephrology, Aso Iizuka Hospital had collected anonymous
47
48
49 data from the participating facilities. In addition, since all patient information analysed in this
50
51
52 study was retrospective, the consent of participants was not obtained. The study results are
53
54
55 reported according to the Strengthening the Reporting of Observational Studies in
56
57
58
59
60

1
2
3
4 Epidemiology (STROBE) guidelines for cohort studies [28]. The data that support the
5
6
7 findings of this study are available from the corresponding author, upon reasonable request.
8
9

10 11 12 13 14 **Study design and participants**

15
16
17 We performed a retrospective cohort study at three academic medical institutions in Japan.
18
19
20 Data were collected from medical records from January 2013 to December 2015 in each
21
22
23 facility. We enrolled consecutive cases on maintenance HD who were of age ≥ 18 years that
24
25
26 had had two sets of blood cultures drawn at admission to assess for the presence of
27
28
29 bacteremia. Cases of hospitalised patients who had been transferred from another hospital,
30
31
32 who had a vintage of dialysis < 2 months, who were also undergoing peritoneal dialysis (PD),
33
34
35 and who were receiving HD less than once a week were excluded (Fig. 1).
36
37
38
39
40
41
42
43

44 **ALP levels**

45
46
47 Admission ALP levels were dichotomized using the upper limit of normal range of 360 U/L
48
49
50 as the cut-off value.
51
52
53
54
55
56

57 **Outcomes**

58
59
60

1
2
3
4 The primary outcome was bacteremia, which was diagnosed based on the results of
5
6
7 admission blood cultures. To avoid misclassification of the primary outcome, an external
8
9
10 consensus panel of infectious disease physicians who have more than ten years clinical
11
12
13 experience and Japanese board of infectious disease determined whether a culture was
14
15
16 contaminated or not based on the conventional definition of contamination and their clinical
17
18
19 expertise. Contamination was defined as: only one of the two sets of culture bottles was
20
21
22 positive; or the presence of certain species of bacteria, such as diphtheroids, *Bacillus* spp.,
23
24
25 *Propionibacterium* sp., *Micrococci*, *Corynebacterium* spp., and coagulase-negative
26
27
28 staphylococci. The secondary outcome was in-hospital death.
29
30
31
32
33

34 **Other Covariates**

35
36
37 Clinical information collected on hospital admission included age, sex, body temperature,
38
39
40 systolic blood pressure, diastolic blood pressure, pulse rate, respiratory rate, haemodialysis
41
42
43 vintage, presence or absence of diabetes mellitus, and use of vitamin D analogues. In addition,
44
45
46 white blood cell counts (WBC), aspartate aminotransferase (AST), total bilirubin (T-BIL),
47
48
49 corrected calcium (cCa), phosphate (P), and C-reactive protein (CRP) were obtained from
50
51
52
53
54 medical records.
55
56
57
58
59
60

Statistical analysis

The patients' baseline characteristics stratified by ALP categorised with the cut-off of normal range of 360 U/L at diagnosis were expressed as medians (quartile) or numbers (%).

Multivariate analysis was performed using five models for bacteremia, the primary outcome, adjusted for age, sex, aspartate aminotransferase (AST), vitamin D analogue use, and haemodialysis vintage. Six models were used for the secondary outcome, in-hospital death, adjusted for age, sex, AST, T-BIL, vitamin D analogue use, cCa, P, haemodialysis vintage, and presence of bacteremia using a logistic regression model. We selected variables for multivariate analysis through a literature review and based on clinical experience. To minimize the bias from missing data, all missing values were imputed using multiple imputation by chained equation (MICE) treated as missing at random including ALP; ten imputed datasets were created [29]. On multivariate analysis, these ten datasets were combined with Rubin's rules and analysed. Analyses were assessed at two-tailed alpha = 0.05. We used commercial software (STATA 15.0, StataCorp LP, College Station, TX, USA) for statistical analysis.

Sample Size

We estimated the prevalence of bacteremia in maintenance HD patients suspected to have bacteremia to be 16% based on a previous report [26]. Since we planned a logistic regression analysis with five explanatory variables, we estimated that the number of bacteremia cases was required to be 50, following the rule of requiring ten outcomes per explanatory variable [30]. From these, it was estimated that a total of 312 subjects were needed.

Sensitivity analysis

To demonstrate the robustness of our inferences, we conducted a complete case analysis for ALP as a sensitivity analysis, which meant excluding participants missing admission ALP.

RESULTS

After the sampling, 315 cases that met the eligibility criteria were included in the study, as shown in Figure 1. Table 1 shows the baseline characteristics of the cohort.

Table 1. Baseline characteristics

	ALP ≤ 360 U/L N = 133	ALP > 360 U/L N = 54	Total N = 315	Missing (N)
Age, years mean (range)	73 (66, 80)	72 (62, 79)	73 (63, 80)	0
Sex	-	-	-	0
males, n (%)	77 (57.9)	26 (48.1)	178 (56.5)	
females, n (%)	56 (42.1)	28 (51.9)	137 (43.5)	

Diabetes mellitus, n (%)	64 (48.1)	27 (50.0)	159 (50.5)	0
Mean systolic blood pressure, mmHg, (range)	134 (110, 150)	134 (11, 150)	134 (110, 150)	2
Mean diastolic blood pressure, mmHg, (range)	70 (60, 80)	70 (60, 80)	70 (60, 80)	22
Mean pulse rate, beats/minute, (range)	90 (78, 102)	92 (84, 108)	90 (78, 102)	4
Mean respiratory rate, per minute, (range)	20 (18, 24)	20 (18, 24)	20 (18, 24)	43
Mean body temperature, °C, (range)	37.3 (36.5, 38.0)	37.6 (36.9, 38.3)	37.2 (36.5, 38.0)	6
Laboratory data				
Mean WBC $\times 10^3/\mu\text{L}$, range	8.7 (6.2, 12.4)	8.6 (6.1, 11.3)	8.4 (6.2, 12.0)	2
Mean AST (U/L), range	17 (12, 25)	24 (18, 55)	18 (13, 25)	7
Mean ALT (U/L), range	10 (7, 15)	18 (12, 38)	11 (7.5, 17)	7
Mean T-Bill (mg/dl), range	0.5 (0.3, 0.6)	0.6 (0.4, 1.5)	0.5 (0.3, 0.7)	17
Mean Ca (mg/dl), range	8.8 (8.4, 9.3)	8.7 (8.3, 9.4)	8.8 (8.4, 9.4)	93
Mean P (mg/dl), range	4.4 (3.3, 5.8)	5.3 (4.1, 6.6)	4.7 (3.8, 6.1)	284
Mean CRP (mg/dL), range	5.2 (2.1, 11.2)	6.0 (1.5, 12.3)	5.5 (2.1, 12.1)	31
Mean haemodialysis vintage, months, (range)	51 (17.5, 114)	58 (18, 139)	55 (20, 115)	14
Vitamin D analogue use, n (%)	60 (45.1)	25 (46.3)	134 (42.5)	2
Vascular access				
arteriovenous fistula, n (%)	86 (64.7)	44 (81.5)	130 (41.3)	0
arteriovenous graft, n (%)	11 (8.3)	2 (3.7)	13 (4.1)	0
arteriovenous shunt, n (%)	5 (3.8)	2 (3.7)	7 (2.2)	0
temporary catheter, n (%)	30 (22.6)	6 (11.1)	36 (11.4)	0

This table shows the baseline characteristics of the cohort.

Abbreviation: ALP, alkaline phosphatase; WBC, white blood cells; AST, aspartate aminotransferase; ALT, alanine aminotransferase; T-Bil, total bilirubin; Ca, calcium; P, phosphorus; CRP, C-reactive protein

Occurrence of Outcomes

Table 2 shows the incidence of bacteremia and in-hospital deaths in the total and groups stratified by ALP. The high-ALP group had a higher incidence of bacteremia.

Table 2. Incidence of bacteraemia and in-hospital death in the total and groups stratified by ALP

	ALP \leq 360 U/L N = 133	ALP $>$ 360 U/L N = 54	total N = 315	Missing (N)
Bacteraemia, n (%)	20 (15.0)	19 (35.2)	50 (15.9)	0
In-hospital death, n (%)	17 (12.8)	9 (16.7)	48 (15.2)	0

This table shows the incidence of bacteremia and in-hospital deaths in the total and groups stratified by ALP. The high-ALP group had a higher incidence of bacteremia.

Abbreviations: ALP, alkaline phosphatase

Association of ALP in hospital visit and bacteremia

In multivariate analysis shown in Figure 2, there was a statistically significant association between higher ALP in hospital visit and bacteremia in all four models.

Association of ALP in hospital visit and in-hospital death

As shown in Figure 2, there were no statistically significant associations between higher ALP and in-hospital death in all five models.

Sensitivity Analysis

To examine the robustness of the findings, we conducted a complete case analysis for ALP excluding participants who were missing ALP values. A sensitivity analysis of 187 patients with no missing ALP values also demonstrated a significant association between ALP and bacteremia, but no significant association between ALP and in-hospital death (Figs. 2).

DISCUSSION

1
2
3
4 This study showed a statistically significant positive correlation between ALP levels and
5
6
7 bacteremia in HD patients suspected of having bacteremia in the outpatient setting. Few
8
9
10 studies examining the association between serum ALP and short-term prognosis have been
11
12
13 reported. This is the first multicentre investigation of the association between ALP levels and
14
15
16 bacteremia or death in patients on maintenance HD.
17
18
19

20
21 Based on the results of this study, elevated serum ALP levels in haemodialysis
22
23 patients suspected of bacteremia could allow for early recognition and may potentially allow
24
25
26 for earlier medical intervention.
27
28
29

30
31 We considered two reasons why elevated ALP levels were associated with
32
33 bacteremia.
34
35
36

37
38 The first is a hypothesis that hepatobiliary infections such as cholangitis cause
39
40 bacteremia or sepsis, leading to elevated ALP levels [31,32]. However, since the main cause
41
42
43 of bacteremia in HD patients is bloodstream infection with staphylococci, it is considered that
44
45
46 bacteremia due to biliary tract infection does not significantly affect ALP levels in this
47
48
49 population. In addition, we adjusted for the liver enzyme AST in multivariate analysis, but
50
51
52 the changes in the OR of bacteremia were small. These findings suggest that the increase in
53
54
55 ALP levels in HD patients is due to factors other than hepatobiliary infection.
56
57
58
59
60

1
2
3
4 We then considered a biological response to bacteremia. Previous studies have
5
6
7
8 shown that ALP acts on inflammatory mediators, such as bacterial endotoxin and
9
10
11 extracellular adenosine triphosphate, and may detoxify them via dephosphorylation
12
13
14 [10,12,33–35]. Previous studies using sepsis in animal models (mice, rats, sheep, piglets)
15
16
17 have reported that treatment with ALP reduced systemic inflammation and organ dysfunction,
18
19
20 and improved survival [36–41]. There are also reports suggesting that ALP may be effective
21
22
23 in the treatment of sepsis in HD patients [42]. Sepsis-related AKI is a result of a combination
24
25
26 of inflammatory, nephrotoxic, and ischemic injuries and is believed to cause rapid
27
28
29 development of renal damage. Pickkers et al. showed that treatment with ALP improved
30
31
32 creatinine clearance; as well as the need for, and duration of, dialysis in patients with AKI
33
34
35 due to sepsis [43].
36
37
38
39
40

41 From these studies, it is clear that elevation of ALP is a response to inflammation
42
43
44 and bacteremia, suggested the relationship between ALP and sepsis.
45
46
47

48 It is known that percutaneous bloodstream infections mainly caused by
49
50
51 gram-positive cocci (GPC) are common in HD patients [44]. However, previous
52
53
54 meta-analysis review reported that about 20% of hemodialysis catheter-related bacteremia
55
56
57
58
59
60

1
2
3
4 were caused by gram-negative rods (GNR) as well as coagulase-negative staphylococci and
5
6
7
8 *staphylococcus aureus* [45].
9

10
11 In our study, GNR-induced sepsis accounted for 34% of cases, which may have been
12
13
14 associated with ALP levels. However, the median values (quartiles) of ALP in bacteremia
15
16
17 due to GPC and GNR were 302 (217, 455) U/L and 388 (225-530) U/L, and there may be
18
19
20 reasons other than this hypothesis. Second, given the mechanism by which GPC inactivates
21
22
23 inflammatory mediators, ALP can be elevated not only by GNR but also by GPC-induced
24
25
26 sepsis [46]. From the above, it is considered that ALP is associated with bacteremia in HD
27
28
29 patients regardless of the category of bacteremia.
30
31
32

33
34 We found no significant association of ALP with mortality in the analysis for
35
36
37 secondary outcome, different from previous studies [10,15,47]. In previous study, HD
38
39
40 patients with elevated ALP levels had an approximately 50% higher risk of sepsis compared
41
42
43 to those with normal ALP levels [15]. It is possible that the overall good prognosis among
44
45
46 patients on maintenance HD in Japan influenced the results.
47
48
49

50
51 Our study has several potential limitations. First, there may be unmeasured
52
53
54 confounding factors, a limit of observational studies. However, it was designed to optimise
55
56
57 the selection of the adjusted confounding factors and to minimise their effect as compared
58
59
60

1
2
3
4 with previous studies. Second, since it is a cross-sectional study, the effect of causal reversal
5
6
7 cannot be denied. However, high ALP levels were shown to be a predictor of bacteremia.
8
9

10
11 Third, this was a retrospective study, and the uncertainty of the data extracted from medical
12
13 records cannot be ruled out. Fourth, while we conducted a multicentre study, the sample size
14
15 was relatively small. This study should facilitate further validation studies to confirm the
16
17 association of ALP elevation and bacteremia in patients on maintenance HD. Lastly, although
18
19 the study sample consisted of patients on maintenance HD from three geographically diverse
20
21 hospitals in Japan, our inferences may not be generalisable to patients on maintenance HD in
22
23 other clinical settings (e.g., patients with hospitalisation at index dates). Nonetheless, our
24
25 inferences should remain relevant for over 340,000 patients on maintenance HD in Japan, a
26
27 vulnerable population with high mortality, about 14 times compared to the general population,
28
29 from bacteremia [48].
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **CONCLUSIONS**

49
50
51 By conducting a multicentre retrospective observational study, we identified elevation of
52
53 ALP levels as an independent predictor of bacteremia among maintenance HD outpatients
54
55 suspected of having sepsis. The association remained consistent after adjusting for other
56
57
58
59
60

1
2
3
4 potential predictors for bacteremia. For clinicians, our data could provide an evidence base
5
6
7 for the early identification of patients with bacteremia and their resultant prompt
8
9
10 hospitalisation. Our findings should facilitate further research to investigate any causal
11
12
13 association of ALP elevation with bacteremia in complex biological systems.
14
15
16
17
18
19
20

21 **Contributors:** All authors have read and approved the submission of the manuscript; the
22
23 manuscript has not been published and is not being considered for publication elsewhere, in
24
25
26
27 whole or in part, in any language, except as an abstract. Sho Sasaki (SS) created the study
28
29
30 design. SS, Yoshihiko Raita, Shungo Yamamoto, Kentaro Tochitani, Minoru Murakami, and
31
32
33 Ryo Nishioka performed data collection. Aya Katasako and SS analysed data, and wrote the
34
35
36
37 article. All authors reviewed the manuscript. Kiichiro Fujisaki approved the submission of
38
39
40 the article.
41
42
43

44 **Competing interests:** All of authors declare that they have no relevant financial interests.
45
46

47 **Patient consent for publication:** Not required
48
49

50 **Funding:** None declared.
51
52

53 **Data sharing statement:** No additional data available
54
55
56
57
58
59
60

Acknowledgment

We thank Libby Cone, MD, MA, from DMC Corp.

(www.dmed.co.jp <<http://www.dmed.co.jp/>>) for editing drafts of this manuscript.

REFERENCES

1. Pruthi R, Steenkamp R, Feest T. UK Renal Registry 16th annual report: chapter 8 survival and cause of death of UK adult patients on renal replacement therapy in 2012: national and centre-specific analyses. *Nephron Clin Pract* 2013;125:139–69.
2. The Japanese Society for Dialysis Therapy.
<https://docs.jsdt.or.jp/overview/file/2019/pdf/02.pdf>
3. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. *J Am Soc Nephrol* 1998;9:869–876.
4. Dopirak M, Hill C, Oleksiw M, et al. Surveillance of hemodialysis-associated primary bloodstream infections: the experience of ten hospital-based centers. *Infect Control Hosp Epidemiol* 2002;23:721–724.

- 1
2
3
4 5. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal
5
6
7
8 disease compared with the general population. *Kidney Int* 2000; 58:1758–1764.
9
- 10
11 6. Eleftheriadis T, Liakopoulos V, Leivaditis K, Antoniadi G, Stefanidis I. Infections in
12
13
14 hemodialysis: a concise review-Part 1: bacteremia and respiratory infections.
15
16
17
18 *Hippokratia* 2011;15:12–17.
19
- 20
21 7. Foley RN, Guo H, Snyder JJ, Gilbertson DT, Collins AJ. Septicemia in the United
22
23
24 States dialysis population, 1991 to 1999. *J Am Soc Nephrol* 2004;15:1038–1045.
25
26
- 27
28 8. Rhee CM, Molnar MZ, Lau WL, et al. Comparative mortality-predictability using
29
30
31 alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and
32
33
34 hemodialysis. *Perit Dial Int* 2014;34:732–748.
35
36
- 37
38 9. Owaki A, Inaguma D, Tanaka A, Shinjo H, Inaba S, Kurata K. Evaluation of the
39
40
41 relationship between the serum alkaline phosphatase level at dialysis initiation and
42
43
44 all-cause mortality: a multicenter, prospective study. *Nephron Extra* 2017;7:78–88.
45
46
- 47
48 10. Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts
49
50
51 mortality among maintenance hemodialysis patients. *J Am Soc Nephrol*
52
53
54 2008;19:2193–2203.
55
56
57
58
59
60

- 1
2
3
4 11. Liu X, Guo Q, Feng X, et al. Alkaline phosphatase and mortality in patients on
5
6
7
8 peritoneal dialysis. *Clin J Am Soc Nephrol* 2014;9:771–778.
9
- 10
11 12. Kovesdy CP, Ureche V, Lu JL, Kalantar-Zadeh K. Outcome predictability of serum
12
13
14
15 alkaline phosphatase in men with pre-dialysis CKD. *Nephrol Dial Transplant*
16
17
18 2010;25:3003–3011.
19
- 20
21 13. Beddhu S, Ma X, Baird B, Cheung AK, Greene T. Serum alkaline phosphatase and
22
23
24
25 mortality in African Americans with chronic kidney disease. *Clin J Am Soc Nephrol*
26
27
28 2009;4:1805–1810.
29
- 30
31 14. Taliercio JJ, Schold JD, Simon JF, et al. Prognostic importance of serum alkaline
32
33
34
35 phosphatase in CKD stages 3-4 in a clinical population. *Am J Kidney Dis*
36
37
38 2013;62:703–710.
39
- 40
41 15. Blayney MJ, Pisoni RL, Bragg-Gresham JL, et al. High alkaline phosphatase levels in
42
43
44
45 hemodialysis patients are associated with higher risk of hospitalization and death.
46
47
48 *Kidney Int* 2008;74:655–663.
49
- 50
51 16. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of
52
53
54
55 time-varying indicators of bone disease in maintenance hemodialysis patients. *Kidney*
56
57
58 *Int* 2006;70:771–780.
59
60

- 1
2
3
4 17. Kerner A, Avizohar O, Sella R, et al. Association between elevated liver enzymes and
5
6
7 C-reactive protein: Possible hepatic contribution to systemic inflammation in the
8
9
10
11 metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2005;25:193–197.
12
13
- 14 18. Schoppet M, Shanahan CM. Role for alkaline phosphatase as an inducer of vascular
15
16
17 calcification in renal failure? *Kidney Int* 2008;73:989–991.
18
19
- 20 19. Lomashvili KA, Garg P, Narisawa S, Millán JL, O’Neill WC. Upregulation of alkaline
21
22
23 phosphatase and pyrophosphate hydrolysis: Potential mechanism for uremic vascular
24
25
26 calcification. *Kidney Int* 2008;73:1024–1030.
27
28
- 29 20. Allon M, Depner TA, Radeva M, et al. Impact of dialysis dose and membrane on
30
31
32 infection-related hospitalization and death: Results of the HEMO Study. *J Am Soc*
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
60
Nephrol 2003;14:1863–1870.
21. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in
end-stage renal disease: A review. *J Am Soc Nephrol* 1993;3:1541–1554.
22. Su G, Liu Z, Qin X, et al. Vitamin D deficiency and treatment versus risk of infection
in end-stage renal disease patients under dialysis: a systematic review and
meta-analysis. *Nephrol Dial Transplant* 2019;34:146–156.


- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
23. Millán JL. Alkaline phosphatases: Structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. *Purinergic Signal* 2006;2:335–341.
24. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2006;69:1945–1953.
25. Damera S, Raphael KL, Baird BC, Cheung AK, Greene T, Beddhu S. Serum alkaline phosphatase levels associate with elevated serum C-reactive protein in chronic kidney disease. *Kidney Int* 2011;79:228–233.
26. Sasaki S, Hasegawa T, Kawarazaki H, et al. Development and validation of a clinical prediction rule for bacteremia among maintenance hemodialysis patients in outpatient settings. *PLoS One* 2017;12: e0181800.
27. Tung CB, Tung CF, Yang DY, et al. Extremely high levels of alkaline phosphatase in adult patients as a manifestation of bacteremia. *Hepatogastroenterology* 2005;52:1347–1350.

- 1
2
3
4 28. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP.
5
6
7 Strengthening the reporting of observational studies in epidemiology (STROBE)
8
9
10
11 statement: guidelines for reporting observational studies. *BMJ*. 2007;335:806–808.
12
13
14 29. Janssen KJM, Donders ART, Harrell FE, et al. Missing covariate data in medical
15
16
17 research: To impute is better than to ignore. *J Clin Epidemiol* 2010;63:721–727.
18
19
20 30. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the
21
22
23 number of events per variable in logistic regression analysis. *J Clin Epidemiol*
24
25
26 1996;49:1373–1379.
27
28
29 31. Gigot JF, Leese T, Dereme T, Coutinho J, Castaing D, Bismuth H. Acute cholangitis.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
31. Gigot JF, Leese T, Dereme T, Coutinho J, Castaing D, Bismuth H. Acute cholangitis. Multivariate analysis of risk factors. *Ann Surg* 1989;209:435–438.
32. Saharia PC, Cameron JL. Clinical management of acute cholangitis. *Surg Gynecol Obstet* 1976;142:369–372.
33. Beumer C, Wulferink M, Raaben W, Fiechter D, Brands R, Seinen W. Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. *J Pharmacol Exp Ther* 2003;307:737–744.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
34. Lallès JP. Intestinal alkaline phosphatase: multiple biological roles in maintenance of intestinal homeostasis and modulation by diet. *Nutr Rev* 2010;68:323–332.
35. Bates JM, Akerlund J, Mittge E, Guillemin K. Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. *Cell Host Microbe* 2007;2:371–382.
36. Bentala H, Verweij WR, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Meijer DK, Poelstra K. Removal of phosphate from lipid a as a strategy to detoxify lipopolysaccharide. *Shock* 2002;18:561–566.
37. Koyama I, Matsunaga T, Harada T, Hokari S, Komoda T. Alkaline phosphatases reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation. *Clin Biochem* 2002;35:455–461.
38. Beumer C, Wulferink M, Raaben W, Fiechter D, Brands R, Seinen W. Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. *J Pharmacol Exp Ther* 2003;307:737–744.

- 1
2
3
4 39. Verweij WR, Bentala H, Huizinga-Van der Vlag A, et al. Protection against an
5
6
7 Escherichia coli-induced sepsis by alkaline phosphatase in mice. Shock 2004;22:174–
8
9
10
11 179.
12
13
14 40. van Veen SQ, van Vliet AK, Wulferink M, Brands R, Boermeester MA, van Gulik TM.
15
16
17 Bovine intestinal alkaline phosphatase attenuates the inflammatory response in
18
19
20 secondary peritonitis in mice. Infect Immun 2005;73:4309–4314.
21
22
23
24 41. Su F, Brands R, Wang Z, et al. Beneficial effects of alkaline phosphatase in septic
25
26
27 shock. Crit Care Med 2006;34:2182–2187.
28
29
30
31 42. Peters E, Heemskerk S, Masereeuw R, Pickkers P. Alkaline phosphatase: A possible
32
33
34 treatment for sepsis-associated acute kidney injury in critically ill patients. Am J
35
36
37 Kidney Dis 2014;63:1038–1048.
38
39
40
41 43. Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of
42
43
44 sepsis-induced acute kidney injury: A prospective randomized double-blind
45
46
47 placebo-controlled trial. Crit Care 2012;16:R14.
48
49
50
51 44. Vandecasteele SJ, Boelaert JR, De Vriese AS: Staphylococcus aureus infections in
52
53
54 hemodialysis: What a nephrologist should know. Clin J Am Soc Nephrol
55
56
57 2009;4:1388–1400.
58
59
60


- 1
2
3
4 45. Aslam S, Vaida F, Ritter M and Mehta RL. Systematic review and meta-analysis on
5
6
7 management of hemodialysis catheter-related bacteremia. *J Am Soc Nephrol*
8
9
10
11 2014;25:2927–2941.
12
13
14 46. Marshall JC, Foster D, Vincent JL, et al. Diagnostic and prognostic implications of
15
16
17 endotoxemia in critical illness: results of the MEDIC study. *J Infect Dis*
18
19
20 2004;190:527–534.
21
22
23
24 47. Hwang SD, Kim SH, Kim YO, et al. Serum alkaline phosphatase levels predict
25
26
27 infection-related mortality and hospitalization in peritoneal dialysis patients. *PLoS*
28
29
30 *One* 2016;11:e0157361.
31
32
33
34 48. Wakasugi M, Kawamura K, Yamamoto S, Kazama JJ, Narita I. High mortality rate of
35
36
37 infectious diseases in dialysis patients: a comparison with the general population in
38
39
40 Japan. *Ther Apher Dial* 2012;16:226–231.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Study Flow

After the sampling, 315 cases that met the eligibility criteria were included.

254x190mm (72 x 72 DPI)

Figure 2. Association between ALP and bacteremia or In-hospital death : logistic regression model



Multivariate analysis shown in this Figure. There were no relationship between higher ALP and in-hospital death, however a statistically significant association between higher ALP and bacteremia.

(Bacteremia outcome) Model 1, adjusted for age, sex; Model 2, Model 1 + aspartate aminotransferase, Model 3, Model 2 + vitamin D analogue use; Model 4, Model 3 + hemodialysis vintage

(In-hospital death outcome) Model 1, adjusted for age, sex; Model 2, Model 1 + aspartate aminotransferase; Model 3, Model 2 + vitamin D analogue use; Model 4, Model 3 + hemodialysis vintage; Model 5, Model 4 + presence of bacteremia

254x190mm (72 x 72 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1 2-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	9
Bias	9	Describe any efforts to address potential sources of bias	9
Study size	10	Explain how the study size was arrived at	9-10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	9-10 9-10 9 9 10
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	10 10 10
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	10-12 10-12 10-12
Outcome data	15*	Report numbers of outcome events or summary measures over time	13

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13
2			(b) Report category boundaries when continuous variables were categorized	13
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
4	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	13
5	Discussion			
6	Key results	18	Summarise key results with reference to study objectives	13-14
7	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14-17
8	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14-17
9	Generalisability	21	Discuss the generalisability (external validity) of the study results	17
10	Other information			
11	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	18

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

The association between serum alkaline phosphatase and bacteraemia in haemodialysis outpatients: A multicentre retrospective cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058666.R1
Article Type:	Original research
Date Submitted by the Author:	22-Apr-2022
Complete List of Authors:	Katasako, Aya; Iizuka Hospital, Department of Nephrology Sasaki, Sho; Iizuka Hospital, Department of Nephrology; Iizuka Hospital, Clinical Research Support Office Raita, Yoshihiko; Okinawa Chubu Hospital, Department of Nephrology Yamamoto, Shungo; Kyoto University Graduate School of Public Health, Department of Healthcare Epidemiology Tochitani, Kentaro; Kyoto University Graduate School of Public Health, Department of Healthcare Epidemiology Murakami, Minoru; Saku Central Hospital, Department of Nephrology Nishioka, Ryo; Ishikawa Prefectural Central Hospital, Department of Nephrology and Rheumatology Fujisaki, Kiichiro; Iizuka Hospital, Department of Nephrology
Primary Subject Heading:	Medical management
Secondary Subject Heading:	Infectious diseases
Keywords:	INFECTIOUS DISEASES, Dialysis < NEPHROLOGY, Nephrology < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 ORIGINAL ARTICLE
5
6
7

8 2 **The association between serum alkaline phosphatase and bacteraemia in haemodialysis**
9
10 3 **outpatients: A multicentre retrospective cross-sectional study**
11
12
13
14 4

15
16
17 5 Aya Katasako, MD^{1†}, Sho Sasaki, MD, DrPH^{1,2†}, Yoshihiko Raita, MD, MPH, MMSc³,

18
19
20 6 Shungo Yamamoto, MD, DrPH⁴, Kentaro Tochitani, MD⁴, Minoru Murakami, MD, MPH⁵,

21
22
23
24 7 Ryo Nishioka, MD⁶, Kiichiro Fujisaki, MD, PhD¹
25
26
27
28 8

29
30
31 9 ¹Department of Nephrology, Iizuka Hospital, Iizuka, Japan, ²Clinical Research Support

32
33
34 10 Office, Iizuka Hospital, Iizuka, Japan, ³Department of Nephrology, Okinawa Chubu Hospital,

35
36
37 11 Uruma, Japan. ⁴Department of Healthcare Epidemiology, Kyoto University Graduate School

38
39
40 12 of Public Health, Kyoto, Japan, ⁵Department of Nephrology, Saku Central Hospital, Nagano,

41
42
43
44 13 Japan, ⁶Department of Nephrology and Rheumatology, Ishikawa Prefectural Central

45
46
47 14 Hospital, Kanazawa, Japan
48
49
50
51 15

52
53
54 16 [†]These authors contributed equally to this work.
55
56
57
58 17
59
60

1
2
3
4 1 Correspondence to:
5

6
7 2 Sho Sasaki, MD, DrPH
8

9
10 3 Department of Nephrology/Clinical Research Support Office, Iizuka Hospital, Fukuoka,
11
12

13
14 4 JAPAN
15

16
17 5 3-83 Yoshio-machi, Iizuka City, Fukuoka, 820-8505, JAPAN
18
19

20 6 E-mail address: ssasakih4@aih-net.com
21
22

23
24 7
25

26
27 8 Total word count: 2789 words
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **1 ABSTRACT (292 words)**
5
6

7 **2 Objectives:** Elevated baseline serum alkaline phosphatase (ALP) may correlate with higher
8
9
10
11 3 medium- to long-term mortality in the general population and in chronic kidney disease
12
13
14 4 (CKD) patients. There are few data on the association between serum ALP and the short-term
15
16
17 5 prognosis of patients on haemodialysis (HD). We verified the association of ALP levels and
18
19
20
21 6 bacteraemia or death in maintenance HD patients suspected of bacteraemia in an outpatient
22
23
24 7 setting.
25
26

27 **8 Design:** We analysed 315 consecutive HD patients suspected of having bacteraemia with two
28
29
30
31 9 sets of blood cultures drawn upon admission.
32
33

34 **10 Setting:** Patients were admitted to one of two tertiary-care university medical centres from
35
36
37 11 January 2013 to December 2015.
38
39
40

41 **12 Participants:** We enrolled consecutive cases on maintenance HD who were aged ≥ 18 years.
42
43
44 13 Cases of hospitalised patients who had been transferred from another hospital, had a dialysis
45
46
47 14 vintage < 2 months, were also undergoing peritoneal dialysis (PD), and/or were receiving HD
48
49
50
51 15 less than once a week were excluded.
52
53

54 **16 Primary and secondary outcome measures:** The primary outcome measure was
55
56
57 17 bacteraemia and the secondary outcome was in-hospital death.
58
59
60

1
2
3
4 **Results:** Among 315 cases included in the study, 187 had baseline-measured ALP levels. The
5
6
7
8 high-ALP group had a higher incidence of bacteraemia. In multivariate analysis, there was a
9
10
11 statistically significant association between a higher ALP in hospital visit and bacteraemia
12
13
14 (OR: 2.37, 95% CI: 1.17 to 4.83). However, there were no statistically significant
15
16
17
18 associations between higher ALP and in-hospital death (OR: 1.20, 95% CI: 0.57 to 2.54). A
19
20
21 sensitivity analysis of 187 patients with no missing ALP values also demonstrated a
22
23
24 significant association between elevated ALP and bacteraemia, but no significant association
25
26
27
28 between ALP and in-hospital death.

29
30 **Conclusions:** Elevated ALP is a predictor of bacteraemia. In HD patients suspected of
31
32
33
34 bacteraemia in outpatient settings, increased ALP levels heighten its likelihood.
35
36

37 **Trial registration:** none
38
39
40
41
42
43

44 **Strengths and limitations of this study:**

- 45
46
47
48 • This is the first multicentre investigation of the association between ALP levels and
49
50
51 bacteraemia or death in patients on maintenance HD.
52
53
54 • Elevated serum ALP levels in haemodialysis patients suspected of bacteraemia could lead to
55
56
57 earlier diagnosis and may potentially allow for earlier medical intervention.
58
59
60

- 1
2
3
4 1 •Our findings should facilitate further research to investigate any causal association of ALP
5
6
7
8 2 elevation with bacteraemia in complex biological systems.
9
10
11 3 •Although the study sample consisted of patients on maintenance HD from two
12
13
14 4 geographically diverse hospitals in Japan, our inferences may not be generalisable to patients
15
16
17 5 on maintenance HD in other clinical settings.
18
19
20
21 6
22
23

24 7 **Keywords:** alkaline phosphatase, bacteraemia, haemodialysis, mortality, prognostic indicator
25
26
27
28 8
29
30

31 9 INTRODUCTION

32
33
34 10 In patients on haemodialysis (HD), it is well known that the second-most common cause of
35
36
37 11 death after cardiovascular events is infection, especially sepsis or bacteraemia[1,2]. The
38
39
40
41 12 prevalence of bacteraemia in patients with HD is 10 to 40 times that in the general
42
43
44 13 population[3,4] with a 50-fold increase in mortality[5–7].
45
46
47

48 14 Multiple studies have shown a positive relationship between serum alkaline
49
50
51 15 phosphatase (ALP) and medium- to long-term mortality in the general population and in
52
53
54 16 chronic kidney disease (CKD) patients, including those on haemodialysis and peritoneal
55
56
57 17 dialysis[8–16]. The explanation is that elevated levels of serum ALP may reflect
58
59
60

1
2
3
4 1 abnormalities such as arterial stiffness, renal osteodystrophy, and inflammation[11,12,17–
5
6
7
8 2 19].
9

10
11 3 In addition to the relationship between serum ALP and mid- to long-term prognosis,
12
13
14 4 observational studies have identified other risk factors for bacteraemia in dialysis patients,
15
16
17 5 including leukocyte dysfunction, malnutrition, parathyroid hormone derangements, and
18
19
20
21 6 vitamin D deficiency[8,20–22].
22
23

24 7 We focused on ALP, an enzyme that hydrolyses phosphate monoester. It is a dimer
25
26
27 8 consisting of two identical molecules, and is expressed as four isoenzymes (placental, germ
28
29
30
31 9 cell, intestinal, and tissue-nonspecific [liver/bone/kidney])[23]. ALP is known as an indicator
32
33
34 10 of renal osteodystrophy, associated with its close relationship with bone, parathyroid gland
35
36
37
38 11 function, the GI tract, and overall mineral balance[24]. Historically, high ALP levels have
39
40
41 12 been considered related to renal osteodystrophy.
42
43

44 13 Damera et al. reported that ALP is one of the inflammatory markers which are
45
46
47 14 independent of 25-OH vitamin D levels in CKD[25]. In addition, the ‘BAC-HD’ (Body
48
49
50
51 15 temperature $\geq 38.3^{\circ}\text{C}$, ALP > 360 U/L, C-reactive protein [CRP] \geq CRP 10 mg/dL, Heart rate
52
53
54 16 ≥ 125 bpm, Drugs: no prior antibiotic use for 1 week) score[26], which we previously
55
56
57
58 17 developed, is a clinical prediction algorithm for bacteraemia among patients with HD.
59
60

1 Tung et al. showed that extremely high ALP levels (ALP > 1000 U/L) were
2 associated with bacteraemia[27]. However, that study had a very small sample size of 16. In
3 other words, there are few studies showing an association between serum ALP and short-term
4 prognosis of bacteraemia and in-hospital mortality.

5 ALP levels can be measured easily and are a less burdensome test for the patient. In
6 addition, bacteraemia is an important outcome for haemodialysis patients because of its high
7 morbidity and mortality. Therefore, it is important to investigate serum ALP levels as
8 predictive markers of bacteraemia. Our aim was to verify the association of ALP levels and
9 bacteraemia or death in maintenance HD patients suspected of bacteraemia in an outpatient
10 setting.

11

12 **METHODS**

13 This study was approved by the ethics committees of Aso Iizuka Hospital (No. 17167),
14 Okinawa Chubu Hospital (H28_No. 51), and Saku Central Hospital (201701-01), and was
15 conducted in accordance with the ethical standards of the Declaration of Helsinki. In the
16 present study, the Department of Nephrology of Aso Iizuka Hospital had collected
17 anonymous data from the participating facilities. Since this study was retrospective, the

1 consent of participants was not obtained. The study results are reported according to the
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 consent of participants was not obtained. The study results are reported according to the
2 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines
3 for cross-sectional studies[28].

5 **Study design and participants**

6 We performed a cross-sectional study at the three academic medical institutions mentioned
7 above. Data were collected from medical records from January 2013 to December 2015 in
8 each facility. We enrolled consecutive cases of patients on maintenance HD who were aged \geq
9 18 years and had had two sets of blood cultures drawn at admission to assess for the presence
10 of bacteraemia. Cases of hospitalised patients who had been transferred from another
11 hospital, had a vintage of dialysis < 2 months, were also undergoing peritoneal dialysis (PD),
12 or were receiving HD less than once a week were excluded (Fig. 1).

14 **ALP levels**

15 Logistic regression analysis was performed with bacteraemia as the dependent variable and
16 ALP as the explanatory variable. Based on the ROC analysis, the value with the highest
17 discriminatory power was used as the cut-off point.

1

2 **Outcomes**

3 The primary outcome was bacteraemia, which was diagnosed based on the results of

4 admission blood cultures. To avoid misclassification of the primary outcome, an external

5 consensus panel of infectious disease physicians with more than ten years' clinical

6 experience and Japanese board certification in infectious disease determined whether a

7 culture was contaminated or not based on the conventional definition of contamination and

8 their clinical expertise. Contamination was defined as: only one of the two sets of culture

9 bottles was positive; or the presence of certain species of bacteria, such as diphtheroids,

10 *Bacillus* spp., *Propionibacterium* spp., *Micrococci* spp., *Corynebacterium* spp., and

11 coagulase-negative staphylococci. The secondary outcome was in-hospital death.

12

13 **Other Covariates**

14 Clinical information collected on hospital admission included age, sex, body temperature,

15 systolic and diastolic blood pressure, pulse rate, respiratory rate, haemodialysis vintage,

16 presence or absence of diabetes mellitus, and use of vitamin D analogues. In addition, white

17 blood cell counts (WBC), aspartate aminotransferase (AST), total bilirubin (T-BIL),

1 corrected calcium (cCa), phosphate (P), and C-reactive protein (CRP) were obtained from
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 corrected calcium (cCa), phosphate (P), and C-reactive protein (CRP) were obtained from
2 medical records.

4 **Statistical analysis**

5 The serum ALP levels at diagnosis were stratified by the cut-off value based on ROC
6 analysis, and patients' baseline characteristics were expressed as medians (quartile) or
7 numbers (%). Multivariate analysis was performed for the primary outcome of bacteraemia in
8 four models adjusted for age, sex, aspartate aminotransferase (AST), vitamin D analogue use,
9 and haemodialysis vintage. Five models were used for the secondary outcome: in-hospital
10 death, adjusted for age, sex, AST, T-BIL, vitamin D analogue use, cCa, P, haemodialysis
11 vintage, and presence of bacteraemia using a logistic regression model (Fig. 2). We selected
12 variables for multivariate analysis through a literature review and based on clinical
13 experience. To minimise the bias from missing data, all missing values were imputed using
14 multiple imputation by chained equation (MICE) treated as missing at random including
15 ALP; ten imputed datasets were created[29]. On multivariate analysis, these ten datasets were
16 combined with Rubin's rules and analysed. Analyses were assessed at a two-tailed alpha =

1
2
3
4 1 0.05. We used commercial software (STATA 15.0, StataCorp LP, College Station, TX, USA)
5
6
7
8 2 for statistical analysis.
9

10
11 3

14 4 **Sample Size**

17 5 We estimated the prevalence of bacteraemia in maintenance HD patients suspected to have
18
19
20
21 6 bacteraemia to be 16% based on a previous report[26]. Since we planned a logistic regression
22
23
24 7 analysis with five explanatory variables, we estimated that the number of bacteraemia cases
25
26
27
28 8 was required to be 50, following the rule of requiring ten outcomes per explanatory
29
30
31 9 variable[30]. From these, it was estimated that a total of 312 subjects was needed.
32

33
34 10

37 11 **Sensitivity analysis**

40
41 12 To demonstrate the robustness of our inferences, we conducted a complete case analysis for
42
43
44 13 ALP as a sensitivity analysis, which meant excluding participants missing admission ALP.
45
46
47
48 14 In addition, we added CRP, which is not a confounding factor but is a strong prognostic
49
50
51 15 factor, and performed a sensitivity analysis.
52

53
54 16

57 17 **Patient and public involvement**

1 No current patients or members of the public were directly involved in this study.

2

3 RESULTS

4 The cut-off value for ALP was 360 U/L based on ROC analysis. Among the 315 cases
 5 included in the study (Figure 1), 187 had baseline measured ALP levels (133 with normal
 6 levels \leq 360 U/L and 54 with ALP levels $>$ 360 U/L). Table 1 shows the baseline
 7 characteristics of the cohort.

9 **Table 1. Baseline characteristics**

	ALP \leq 360 U/L	ALP $>$ 360 U/L	Total	Missing (N)
	N=133	N=54	N=315	
Age, years, median (IQR)	73 (66, 80)	72 (62, 79)	73 (63, 80)	0
Sex				0
males, n (%)	77 (57.9)	26 (48.1)	178 (56.5)	
females, n (%)	56 (42.1)	28 (51.9)	137 (43.5)	
Diabetes mellitus, n (%)	64 (48.1)	27 (50.0)	159 (50.5)	0
Systolic blood pressure, mmHg, median (IQR)	134 (110, 150)	134 (11, 150)	134 (110, 150)	2
Diastolic blood pressure, mmHg, median (IQR)	70 (60, 80)	70 (60, 80)	70 (60, 80)	22
Pulse rate, beats/minute, median (IQR)	90 (78, 102)	92 (84, 108)	90 (78, 102)	4
Respiratory rate, per minute, median (IQR)	20 (18, 24)	20 (18, 24)	20 (18, 24)	43

Body temperature, °C, median (IQR)	37.3 (36.5, 38.0)	37.6 (36.9, 38.3)	37.2 (36.5, 38.0)	6
Laboratory data				
WBC ($\times 10^3/\mu\text{L}$), median (IQR)	8.7 (6.2, 12.4)	8.6 (6.1, 11.3)	8.4 (6.2, 12.0)	2
ALP (U/L), median (IQR)	-	-	271 (219, 376)	128
AST (U/L), median (IQR)	17 (12, 25)	24 (18, 55)	18 (13, 25)	7
ALT (U/L), median (IQR)	10 (7, 15)	18 (12, 38)	11 (7.5, 17)	7
T-Bil (mg/dl), median (IQR)	0.5 (0.3, 0.6)	0.6 (0.4, 1.5)	0.5 (0.3, 0.7)	17
Ca (mg/dL), median (IQR)	8.8 (8.4, 9.3)	8.7 (8.3, 9.4)	8.8 (8.4, 9.4)	93
P (mg/dL), median (IQR)	4.4 (3.3, 5.8)	5.3 (4.1, 6.6)	4.7 (3.8, 6.1)	284
CRP (mg/dL), median (IQR)	5.2 (2.1, 11.2)	6.0 (1.5, 12.3)	5.5 (2.1, 12.1)	31
Haemodialysis vintage, months, median (IQR)	51 (17.5, 114)	58 (18, 139)	55 (20, 115)	14
Vitamin D analogue use, n (%)	60 (45.1)	25 (46.3)	134 (42.5)	2
Vascular access				
arteriovenous fistula, n (%)	86 (64.7)	44 (81.5)	130 (41.3)	0
arteriovenous graft, n (%)	11 (8.3)	2 (3.7)	13 (4.1)	0
arteriovenous shunt, n (%)	5 (3.8)	2 (3.7)	7 (2.2)	0
temporary catheter, n (%)	30 (22.6)	6 (11.1)	36 (11.4)	0

1

2 This table shows the baseline characteristics of the cohort.

3 Abbreviation: ALP, alkaline phosphatase; WBC, white blood cells; AST, aspartate

4 aminotransferase; ALT, alanine aminotransferase; T-Bil, total bilirubin; Ca, calcium; P,

5 phosphorus; CRP, C-reactive protein; IQR Interquartile range

6

7 **Occurrence of Outcomes**

1 Table 2 shows the incidence of bacteraemia and in-hospital deaths in the total and groups
 2 stratified by ALP. The high-ALP group had a higher incidence of bacteraemia.

3
 4 **Table 2. Incidence of bacteraemia and in-hospital death in the total and groups**
 5 **stratified by ALP**

	ALP ≤ 360 U/L N = 133	ALP > 360 U/L N = 54	total N = 315	Missing (N)
Bacteraemia, n (%)	20 (15.0)	19 (35.2)	50 (15.9)	11
In-hospital death, n (%)	17 (12.8)	9 (16.7)	48 (15.2)	22

6
 7 This table shows the incidence of bacteraemia and in-hospital deaths in the total and groups
 8 stratified by ALP. The high-ALP group had a higher incidence of bacteraemia.

9 Abbreviations: ALP, alkaline phosphatase

10 11 **Association of ALP in hospital visit and bacteraemia**

12 In the multivariate analysis shown in Figure 2, there was a statistically significant association
 13 between higher ALP in hospital visit and bacteraemia in all four models.

1 Association of ALP in hospital visit and in-hospital death

2 As shown in Figure 2, there were no statistically significant associations between higher ALP
3 and in-hospital death in all five models.

4 Sensitivity Analysis

5 To examine the robustness of the findings, we conducted a complete case analysis for ALP
6 excluding participants who were missing ALP values. A sensitivity analysis of the 187
7 patients with no missing ALP values also demonstrated a significant association between
8 ALP and bacteraemia, but no significant association between ALP and in-hospital death (Fig.
9 2). In a sensitivity analysis with the addition of CRP, it did not show a significant association
10 between bacteraemia and ALP levels in analysis adjusted for age, sex, AST, CRP, vitamin D
11 analogue use, or haemodialysis vintage (OR: 1.97, 95% CI: 0.97 to 4.01) as shown in
12 Supplementary Figure.

13 DISCUSSION

14 This study showed a statistically significant positive correlation between ALP levels and
15 bacteraemia in HD patients suspected of having bacteraemia in the outpatient setting. Few
16
17

1
2
3
4 1 studies examining the association between serum ALP and short-term prognosis have been
5
6
7 2 reported. This is the first multicentre investigation of the association between ALP levels and
8
9
10
11 3 bacteraemia or death in patients on maintenance HD.
12
13

14 4 Based on the results of this study, elevated serum ALP levels in haemodialysis
15
16
17 5 patients with suspected bacteraemia could allow for early recognition and may potentially
18
19
20
21 6 allow for earlier medical intervention.
22
23

24 7

27 8 **Association between ALP and bacteraemia**

29
30
31 9 We considered two reasons why elevated ALP levels were associated with bacteraemia. First
32
33
34 10 is the involvement of hepatobiliary infections such as cholangitis. We hypothesise that it may
35
36
37
38 11 cause bacteraemia or sepsis, leading to elevated ALP levels[31,32]. However, since the main
39
40
41 12 cause of bacteraemia in HD patients is bloodstream infection with staphylococci, it is
42
43
44 13 considered that bacteraemia due to biliary tract infection does not significantly affect ALP
45
46
47
48 14 levels in this population. In addition, we adjusted for the liver enzyme AST in multivariate
49
50
51 15 analysis, but the changes in the OR of bacteraemia were small. These findings suggest that
52
53
54 16 the increase in ALP levels in HD patients was due to factors other than hepatobiliary
55
56
57
58 17 infection.
59
60

1
2
3
4 1 Second, we considered a biological response to bacteraemia. Previous studies have
5
6
7
8 2 shown that ALP acts on inflammatory mediators, such as bacterial endotoxin and
9
10
11 3 extracellular adenosine triphosphate, and may detoxify them via
12
13
14 4 dephosphorylation[10,12,33–35]. In animal models of sepsis (mice, rats, sheep, piglets), it has
15
16
17
18 5 been reported that treatment with ALP reduced systemic inflammation and organ
19
20
21 6 dysfunction, and improved survival[33,36–40]. There are also reports suggesting that ALP t
22
23
24 7 is effective in the treatment of sepsis in HD patients[41]. Sepsis-related AKI is thought to be
25
26
27
28 8 the result of a combination of inflammatory, nephrotoxic, and ischemic injury with rapid
29
30
31 9 progression of renal damage. Pickkers et al. showed that treatment with ALP improved
32
33
34 10 creatinine clearance, as well as the need for and duration of dialysis in patients with sepsis-
35
36
37
38 11 related AKI[42].
39
40

41 12 The above two points suggest that the increase in ALP may be a response to
42
43
44 13 inflammation or bacteraemia.
45
46

47
48 14 In maintenance haemodialysis patients with a high risk of infection, the therapeutic
49
50
51 15 strategy, including antimicrobials, is often distressing until the results of blood culture are
52
53
54 16 available. Unnecessary administration of antimicrobials can be harmful to the patient,
55
56
57
58 17 because antimicrobial resistance is a serious problem for them. However, it has also known
59
60

1
2
3
4 1 that delayed administration of empiric antimicrobial therapy leads to increased mortality.[43]
5
6

7
8 2 We need to decide the timing of administration of therapy and choice of antimicrobial agents
9

10
11 3 appropriately. Serum ALP levels have been reported as one example of a simple clinical
12

13
14 4 prediction rule in the bacteraemia 'BAC-HD score'.[44] In maintenance HD outpatients
15

16
17 5 suspected of sepsis, elevated serum ALP levels may indicate the presence of bacteraemia and
18

19
20 6 may aid in the decision to begin early antimicrobial therapy and in the choice of the
21

22
23 7 antimicrobial agent.
24

25
26
27 8
28

29 30 31 9 **ALP isozymes** 32

33
34 10 Intestinal isozyme may be of possible relevance to sepsis-related treatment.[34, 41] However,
35

36
37 11 no association has been found between specific isozymes and bacteraemia or sepsis, and we
38

39
40 12 do not recommend the measurement of isozymes at this time in clinical practice. If the above
41

42
43 13 two points are resolved, it may be useful to measure ALP isozymes in the future.
44
45
46
47
48 14

49 50 51 15 **The species associated with bacteraemia** 52

53
54 16 It is known that percutaneous bloodstream infections caused primarily by gram-positive cocci
55

56
57 17 (GPC) are common in HD patients[45]. However, a previous meta-analysis reported that
58
59
60

1 about 20% of haemodialysis catheter-related bacteraemias were caused by gram-negative
2 rods (GNR) as well as coagulase-negative staphylococci and *Staphylococcus aureus*[46].

3 In our study, GNR-induced sepsis accounted for 34% of cases, which may have been
4 associated with ALP levels. However, the median quartile values of ALP in bacteraemia due
5 to GPC and GNR were 302 (range, 217, 455) U/L and 388 (range, 225, 530) U/L,
6 respectively, and there may be reasons other than this hypothesis. Second, given the
7 mechanism by which GPC inactivates inflammatory mediators, ALP can be elevated not only
8 by GNR but also by GPC-induced sepsis[47]. From the above, it is considered that ALP is
9 associated with bacteraemia in HD patients regardless of the category of the offending
10 bacterium.

11

12 **Association between ALP and mortality**

13 We found no significant association of ALP with mortality in the analysis for secondary
14 outcome, in contrast to previous studies[10,15,48]. In one study, HD patients with elevated
15 ALP levels had an approximately 50% higher risk of infection-related mortality compared to
16 those with normal ALP levels[15]. One reason for the significant difference in bacteraemia

1
2
3
4 1 but not in mortality may be that the overall prognosis for maintenance HD patients in Japan is
5
6
7
8 2 good.

9
10
11 3

14 4 **Limitations**

15
16
17 5 Our study has several limitations. First, there may be unmeasured confounding factors, a
18
19
20
21 6 limit of observational studies. However, it was designed to optimise the selection of the
22
23
24 7 adjusted confounding factors and to minimise their effect as compared with previous studies.
25
26
27 8 Second, since it is a cross-sectional study, the possibility of reverse causation cannot be
28
29
30 9 denied. However, high ALP levels were shown to be a predictor of bacteraemia. Third, this
31
32
33
34 10 was a retrospective study, and the uncertainty of the data extracted from medical records
35
36
37
38 11 cannot be ruled out. Fourth, while we conducted a multicentre study, the sample size was
39
40
41 12 relatively small and there were substantial missing data. In patients with ALP data, there was
42
43
44 13 a statistically significant association between ALP and bacteraemia, but no association
45
46
47
48 14 between ALP and in-hospital mortality. We consider the small sample size as a reason why
49
50
51 15 we could not show an association with mortality, unlike previous reports. This is the first
52
53
54 16 study suggesting that serum ALP is one of several independent predictors of bacteraemia in
55
56
57
58 17 HD patients. Our study should facilitate further validation studies to confirm the association
59
60

1 of ALP elevation and bacteraemia in maintenance HD patients. Fifth, it cannot be determined
2 in this study whether serum ALP levels were elevated before illness or due to bacteraemia.
3 However, baseline serum ALP levels are often unknown in clinical practice. Therefore we
4 consider it may be clinically acceptable. Lastly, the study sample consisted of patients on
5 maintenance HD from three geographically diverse hospitals in Japan, and our findings may
6 not be generalisable to patients on maintenance HD in other clinical settings (e.g., patients
7 with hospitalisation at index dates). Nonetheless, our inferences should remain relevant for
8 over 340,000 patients on maintenance HD in Japan, a vulnerable population with high
9 mortality from bacteraemia, at about 14 times that of the general population [49].

10

11 **CONCLUSIONS**

12 By conducting a multicentre retrospective observational study, we identified elevation of
13 ALP levels as an independent predictor of bacteraemia among maintenance HD outpatients
14 suspected of having sepsis. The association remained consistent after adjusting for other
15 potential predictors for bacteraemia. For clinicians, our data could provide an evidence base
16 for the early identification of patients with bacteraemia and their resultant prompt

1 hospitalisation. Our findings should facilitate further research to investigate any causal
2 association of ALP elevation with bacteraemia in complex biological systems.

3 **Funding:** None declared.

4 **Competing interests:** All of authors declare that they have no relevant financial interests.

5 **Contributors:** All authors have read and approved the submission of the manuscript; the
6 manuscript has not been published and is not being considered for publication elsewhere, in
7 whole or in part, in any language, except as an abstract. Sho Sasaki (SS) created the study
8 design. SS, Yoshihiko Raita, Shungo Yamamoto, Kentaro Tochitani, Minoru Murakami, and
9 Ryo Nishioka performed data collection. Aya Katasako and SS analysed data, and wrote the
10 article. All authors reviewed the manuscript. Kiichiro Fujisaki approved the submission of
11 the article.

12 **Patient consent for publication:** Not required

13 **Data sharing statement:** The data that support the findings of this study are available from
14 the corresponding author upon reasonable request.

15

16

17 **Acknowledgment**

1 We thank Libby Cone, MD, MA, from DMC Corp.

2 (www.dmed.co.jp <<http://www.dmed.co.jp/>>) for editing drafts of this manuscript.

4 REFERENCES

- 5 1. Pruthi R, Steenkamp R, Feest T. UK Renal Registry 16th annual report: chapter 8
6 survival and cause of death of UK adult patients on renal replacement therapy in 2012:
7 national and centre-specific analyses. *Nephron Clin Pract* 2013;125:139–69.
- 8 2. The Japanese Society for Dialysis Therapy.
9 <https://docs.jsdt.or.jp/overview/file/2019/pdf/02.pdf>
- 10 3. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: A multicenter
11 prospective study of risk factors for bacteremia in chronic hemodialysis patients. *J Am*
12 *Soc Nephrol* 1998;9:869–876.
- 13 4. Dopirak M, Hill C, Oleksiw M, et al. Surveillance of hemodialysis-associated primary
14 bloodstream infections: the experience of ten hospital-based centers. *Infect Control*
15 *Hosp Epidemiol* 2002;23:721–724.
- 16 5. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal
17 disease compared with the general population. *Kidney Int* 2000; 58:1758–1764.

- 1
2
3
4 1 6. Eleftheriadis T, Liakopoulos V, Leivaditis K, Antoniadis G, Stefanidis I. Infections in
5
6
7
8 2 hemodialysis: a concise review-Part 1: bacteremia and respiratory infections.
9
10
11 3 Hippokratia 2011;15:12–17.
12
13
14 4 7. Foley RN, Guo H, Snyder JJ, Gilbertson DT, Collins AJ. Septicemia in the United
15
16
17
18 5 States dialysis population, 1991 to 1999. *J Am Soc Nephrol* 2004;15:1038–1045.
19
20
21 6 8. Rhee CM, Molnar MZ, Lau WL, et al. Comparative mortality-predictability using
22
23
24 7 alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and
25
26
27 8 hemodialysis. *Perit Dial Int* 2014;34:732–748.
28
29
30
31 9 9. Owaki A, Inaguma D, Tanaka A, Shinjo H, Inaba S, Kurata K. Evaluation of the
32
33
34 10 relationship between the serum alkaline phosphatase level at dialysis initiation and all-
35
36
37 11 cause mortality: a multicenter, prospective study. *Nephron Extra* 2017;7:78–88.
38
39
40
41 12 10. Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts
42
43
44 13 mortality among maintenance hemodialysis patients. *J Am Soc Nephrol*
45
46
47 14 2008;19:2193–2203.
48
49
50
51 15 11. Liu X, Guo Q, Feng X, et al. Alkaline phosphatase and mortality in patients on
52
53
54 16 peritoneal dialysis. *Clin J Am Soc Nephrol* 2014;9:771–778.
55
56
57
58
59
60

- 1
2
3
4 1 12. Kovesdy CP, Ureche V, Lu JL, Kalantar-Zadeh K. Outcome predictability of serum
5
6
7
8 2 alkaline phosphatase in men with pre-dialysis CKD. *Nephrol Dial Transplant*
9
10
11 3 2010;25:3003–3011.
12
13
14 4 13. Beddhu S, Ma X, Baird B, Cheung AK, Greene T. Serum alkaline phosphatase and
15
16
17 5 mortality in African Americans with chronic kidney disease. *Clin J Am Soc Nephrol*
18
19
20 6 2009;4:1805–1810.
21
22
23
24 7 14. Taliercio JJ, Schold JD, Simon JF, et al. Prognostic importance of serum alkaline
25
26
27 8 phosphatase in CKD stages 3-4 in a clinical population. *Am J Kidney Dis*
28
29
30 9 2013;62:703–710.
31
32
33
34 10 15. Blayney MJ, Pisoni RL, Bragg-Gresham JL, et al. High alkaline phosphatase levels in
35
36
37 11 hemodialysis patients are associated with higher risk of hospitalization and death.
38
39
40 12 *Kidney Int* 2008;74:655–663.
41
42
43
44 13 16. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-
45
46
47 14 varying indicators of bone disease in maintenance hemodialysis patients. *Kidney Int*
48
49
50 15 2006;70:771–780.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 17. Kerner A, Avizohar O, Sella R, et al. Association between elevated liver enzymes and
5
6
7
8 2 C-reactive protein: Possible hepatic contribution to systemic inflammation in the
9
10
11 3 metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2005;25:193–197.
12
13
14 4 18. Schoppet M, Shanahan CM. Role for alkaline phosphatase as an inducer of vascular
15
16
17 5 calcification in renal failure? *Kidney Int* 2008;73:989–991.
18
19
20
21 6 19. Lomashvili KA, Garg P, Narisawa S, Millán JL, O’Neill WC. Upregulation of alkaline
22
23
24 7 phosphatase and pyrophosphate hydrolysis: Potential mechanism for uremic vascular
25
26
27 8 calcification. *Kidney Int* 2008;73:1024–1030.
28
29
30
31 9 20. Allon M, Depner TA, Radeva M, et al. Impact of dialysis dose and membrane on
32
33
34 10 infection-related hospitalization and death: Results of the HEMO Study. *J Am Soc*
35
36
37 11 *Nephrol* 2003;14:1863–1870.
38
39
40
41 12 21. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in
42
43
44 13 end-stage renal disease: A review. *J Am Soc Nephrol* 1993;3:1541–1554.
45
46
47
48 14 22. Su G, Liu Z, Qin X, et al. Vitamin D deficiency and treatment versus risk of infection
49
50
51 15 in end-stage renal disease patients under dialysis: a systematic review and meta-
52
53
54 16 analysis. *Nephrol Dial Transplant* 2019;34:146–156.
55
56
57
58
59
60

- 1
2
3
4 1 23. Millán JL. Alkaline phosphatases: Structure, substrate specificity and functional
5
6
7
8 2 relatedness to other members of a large superfamily of enzymes. *Purinergic Signal*
9
10
11 3 2006;2:335–341.
12
13
14 4 24. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of
15
16
17 5 renal osteodystrophy: a position statement from Kidney Disease: Improving Global
18
19
20 6 Outcomes (KDIGO). *Kidney Int* 2006;69:1945–1953.
21
22
23
24 7 25. Damera S, Raphael KL, Baird BC, Cheung AK, Greene T, Beddhu S. Serum alkaline
25
26
27 8 phosphatase levels associate with elevated serum C-reactive protein in chronic kidney
28
29
30 9 disease. *Kidney Int* 2011;79:228–233.
31
32
33
34 10 26. Sasaki S, Hasegawa T, Kawarazaki H, et al. Development and validation of a clinical
35
36
37 11 prediction rule for bacteremia among maintenance hemodialysis patients in outpatient
38
39
40 12 settings. *PLoS One* 2017;12: e0181800.
41
42
43
44 13 27. Tung CB, Tung CF, Yang DY, et al. Extremely high levels of alkaline phosphatase in
45
46
47 14 adult patients as a manifestation of bacteremia. *Hepatogastroenterology*
48
49
50 15 2005;52:1347–1350.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 1 28. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP.
5
6
7 2 Strengthening the reporting of observational studies in epidemiology (STROBE)
8
9
10 3 statement: guidelines for reporting observational studies. *BMJ*. 2007;335:806–808.
11
12
13
14 4 29. Janssen KJM, Donders ART, Harrell FE, et al. Missing covariate data in medical
15
16
17 5 research: To impute is better than to ignore. *J Clin Epidemiol* 2010;63:721–727.
18
19
20
21 6 30. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the
22
23
24 7 number of events per variable in logistic regression analysis. *J Clin Epidemiol*
25
26
27 8 1996;49:1373–1379.
28
29
30
31 9 31. Gigot JF, Leese T, Dereme T, Coutinho J, Castaing D, Bismuth H. Acute cholangitis.
32
33
34 10 Multivariate analysis of risk factors. *Ann Surg* 1989;209:435–438.
35
36
37
38 11 32. Saharia PC, Cameron JL. Clinical management of acute cholangitis. *Surg Gynecol*
39
40
41 12 *Obstet* 1976;142:369–372.
42
43
44 13 33. Beumer C, Wulferink M, Raaben W, Fiechter D, Brands R, Seinen W. Calf intestinal
45
46
47 14 alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated
48
49
50 15 diseases, attenuates LPS toxicity in mice and piglets. *J Pharmacol Exp Ther*
51
52
53
54 16 2003;307:737–744.
55
56
57
58
59
60

- 1
2
3
4 1 34. Lallès JP. Intestinal alkaline phosphatase: multiple biological roles in maintenance of
5
6
7
8 2 intestinal homeostasis and modulation by diet. *Nutr Rev* 2010;68:323–332.
9
10
11 3 35. Bates JM, Akerlund J, Mittge E, Guillemin K. Intestinal alkaline phosphatase
12
13
14 4 detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to
15
16
17 5 the gut microbiota. *Cell Host Microbe* 2007;2:371–382.
18
19
20
21 6 36. Bentala H, Verweij WR, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Meijer
22
23
24 7 DK, Poelstra K. Removal of phosphate from lipid a as a strategy to detoxify
25
26
27 8 lipopolysaccharide. *Shock* 2002;18:561–566.
28
29
30
31 9 37. Koyama I, Matsunaga T, Harada T, Hokari S, Komoda T. Alkaline phosphatases
32
33
34 10 reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation.
35
36
37 11 *Clin Biochem* 2002;35:455–461.
38
39
40
41 12 38. Verweij WR, Bentala H, Huizinga-Van der Vlag A, et al. Protection against an
42
43
44 13 *Escherichia coli*-induced sepsis by alkaline phosphatase in mice. *Shock* 2004;22:174–
45
46
47 14 179.
48
49
50
51 15 39. van Veen SQ, van Vliet AK, Wulferink M, Brands R, Boermeester MA, van Gulik
52
53
54 16 TM. Bovine intestinal alkaline phosphatase attenuates the inflammatory response in
55
56
57 17 secondary peritonitis in mice. *Infect Immun* 2005;73:4309–4314.
58
59
60

- 1
2
3
4 1 40. Su F, Brands R, Wang Z, et al. Beneficial effects of alkaline phosphatase in septic
5
6
7
8 2 shock. *Crit Care Med* 2006;34:2182–87.
9
10
11 3 41. Peters E, Heemskerk S, Masereeuw R, et al. Alkaline phosphatase: A possible
12
13
14 4 treatment for sepsis-associated acute kidney injury in critically ill patients. *Am J*
15
16
17 5 *Kidney Dis* 2014;63:1038–1048.
18
19
20
21 6 42. Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of
22
23
24 7 sepsis-induced acute kidney injury: A prospective randomized double-blind placebo-
25
26
27 8 controlled trial. *Crit Care* 2012;16:R14.
28
29
30
31 9 43. Lee CC, Lee CH, Yang CY, Hsieh CC, Tang HJ, Ko WC. Beneficial effects of early
32
33
34 10 empirical administration of appropriate antimicrobials on survival and defervescence
35
36
37 11 in adults with community-onset bacteremia. *Critical Care* 2019;23:363.
38
39
40
41 12 44. Sasaki S, Raita Y, Murakami M, et al. Added value of clinical prediction rules for
42
43
44 13 bacteremia in hemodialysis patients: An external validation study. *PLoS One*
45
46
47 14 2021;16(2):e0247624.
48
49
50
51 15 45. Vandecasteele SJ, Boelaert JR, De Vriese AS: Staphylococcus aureus infections in
52
53
54 16 hemodialysis: What a nephrologist should know. *Clin J Am Soc Nephrol*
55
56
57 17 2009;4:1388–1400.
58
59
60

- 1
2
3
4 1 46. Aslam S, Vaida F, Ritter M, Mehta RL. Systematic review and meta-analysis on
5
6
7
8 2 management of hemodialysis catheter-related bacteremia. *J Am Soc Nephrol*
9
10
11 3 2014;25:2927–2941.
12
13
14 4 47. Marshall JC, Foster D, Vincent JL, et al. Diagnostic and prognostic implications of
15
16
17 5 endotoxemia in critical illness: results of the MEDIC study. *J Infect Dis*
18
19
20 6 2004;190:527–534.
21
22
23
24 7 48. Hwang SD, Kim SH, Kim YO, et al. Serum alkaline phosphatase levels predict
25
26
27 8 infection-related mortality and hospitalization in peritoneal dialysis patients. *PLoS*
28
29
30 9 *One* 2016;11:e0157361.
31
32
33
34 10 49. Wakasugi M, Kawamura K, Yamamoto S, Kazama JJ, Narita I. High mortality rate of
35
36
37 11 infectious diseases in dialysis patients: a comparison with the general population in
38
39
40 12 Japan. *Ther Apher Dial* 2012;16:226–231.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

1

2

3 **Figure 1. Study flow**

4 After the sampling, 315 cases that met the eligibility criteria were included.

5

6 **Figure 2. Association between ALP and bacteraemia or In-hospital death: logistic**

7 **regression model**

8 Multivariate analysis shown in this Figure. There was no relationship between higher ALP
9 and in-hospital death, however there was a statistically significant association between higher
10 ALP and bacteraemia.

11 Bacteraemia outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 +

12 aspartate aminotransferase, Model 3, adjusted for Model 2 + vitamin D analogue use; Model

13 4, adjusted for Model 3 + haemodialysis vintage

14 In-hospital death outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 +

15 aspartate aminotransferase; Model 3, adjusted for Model 2 + vitamin D analogue use; Model

16 4, adjusted for Model 3 + haemodialysis vintage; Model 5, adjusted for Model 4 + presence

17 of bacteraemia




Figure 1. Study flow
After the sampling, 315 cases that met the eligibility criteria were included.

254x190mm (96 x 96 DPI)





Figure 2. Association between ALP and bacteraemia or In-hospital death: logistic regression model Multivariate analysis shown in this Figure. There was no relationship between higher ALP and in-hospital death, however there was a statistically significant association between higher ALP and bacteraemia. Bacteraemia outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase, Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 + haemodialysis vintage In-hospital death outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase; Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 + haemodialysis vintage; Model 5, adjusted for Model 4 + presence of bacteraemia

361x203mm (72 x 72 DPI)



Bacteraemia outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase + CRP; Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 + haemodialysis vintage

In-hospital death outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase + CRP; Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 + haemodialysis vintage; Model 5, adjusted for Model 4 + presence of bacteraemia

1-058666 on 7 October 2022. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-5
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-11
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10-11
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10-11
		(b) Describe any methods used to examine subgroups and interactions	10-11
		(c) Explain how missing data were addressed	10-11
		(d) If applicable, describe analytical methods taking account of sampling strategy	10-11
		(e) Describe any sensitivity analyses	11
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	12
		(b) Give reasons for non-participation at each stage	12
		(c) Consider use of a flow diagram	12
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12-13
		(b) Indicate number of participants with missing data for each variable of interest	12-13
Outcome data	15*	Report numbers of outcome events or summary measures	13-15
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13-15

		(b) Report category boundaries when continuous variables were categorized	-
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	15
Discussion			
Key results	18	Summarise key results with reference to study objectives	15-16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	20-21
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	16-21
Generalisability	21	Discuss the generalisability (external validity) of the study results	17-18, 20-21
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	22

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

The association between serum alkaline phosphatase and bacteraemia in haemodialysis outpatients: A multicentre retrospective cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058666.R2
Article Type:	Original research
Date Submitted by the Author:	09-Aug-2022
Complete List of Authors:	Katasako, Aya; Iizuka Hospital, Department of Nephrology Sasaki, Sho; Iizuka Hospital, Department of Nephrology; Iizuka Hospital, Clinical Research Support Office Raita, Yoshihiko; Okinawa Chubu Hospital, Department of Nephrology Yamamoto, Shungo; Kyoto University Graduate School of Public Health, Department of Healthcare Epidemiology Tochitani, Kentaro; Kyoto University Graduate School of Public Health, Department of Healthcare Epidemiology Murakami, Minoru; Saku Central Hospital, Department of Nephrology Nishioka, Ryo; Ishikawa Prefectural Central Hospital, Department of Nephrology and Rheumatology Fujisaki, Kiichiro; Iizuka Hospital, Department of Nephrology
Primary Subject Heading:	Medical management
Secondary Subject Heading:	Infectious diseases
Keywords:	INFECTIOUS DISEASES, Dialysis < NEPHROLOGY, Nephrology < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 ORIGINAL ARTICLE
5
6
7

8 2 **The association between serum alkaline phosphatase and bacteraemia in haemodialysis**
9
10 3 **outpatients: A multicentre retrospective cross-sectional study**
11
12
13
14 4

15
16
17 5 Aya Katasako, MD^{1†}, Sho Sasaki, MD, DrPH^{1,2†}, Yoshihiko Raita, MD, MPH, MMSc³,

18
19
20 6 Shungo Yamamoto, MD, DrPH⁴, Kentaro Tochitani, MD⁴, Minoru Murakami, MD, MPH⁵,

21
22
23
24 7 Ryo Nishioka, MD⁶, Kiichiro Fujisaki, MD, PhD¹
25
26
27
28 8

29
30
31 9 ¹Department of Nephrology, Iizuka Hospital, Iizuka, Japan, ²Clinical Research Support

32
33
34 10 Office, Iizuka Hospital, Iizuka, Japan, ³Department of Nephrology, Okinawa Chubu Hospital,

35
36
37 11 Uruma, Japan. ⁴Department of Healthcare Epidemiology, Kyoto University Graduate School

38
39
40 12 of Public Health, Kyoto, Japan, ⁵Department of Nephrology, Saku Central Hospital, Nagano,

41
42
43
44 13 Japan, ⁶Department of Nephrology and Rheumatology, Ishikawa Prefectural Central

45
46
47 14 Hospital, Kanazawa, Japan
48
49
50
51 15

52
53
54 16 [†]These authors contributed equally to this work.
55
56
57
58 17
59
60

1
2
3
4 1 Correspondence to:
5

6
7 2 Sho Sasaki, MD, DrPH
8

9
10 3 Department of Nephrology/Clinical Research Support Office, Iizuka Hospital, Fukuoka,
11

12
13
14 4 JAPAN
15

16
17 5 3-83 Yoshio-machi, Iizuka City, Fukuoka, 820-8505, JAPAN
18

19
20 6 E-mail address: ssasakih4@aih-net.com
21

22
23
24 7
25

26
27 8 Total word count: 3102 words
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **1 ABSTRACT (292 words)**
5

6
7 **2 Objectives:** Elevated baseline serum alkaline phosphatase (ALP) may correlate with higher
8
9
10
11 **3** medium- to long-term mortality in the general population and in chronic kidney disease
12
13
14 **4** (CKD) patients. There are few data on the association between serum ALP and the short-term
15
16
17 **5** prognosis of patients on haemodialysis (HD). We verified the association of ALP levels and
18
19
20
21 **6** bacteraemia or death in maintenance HD patients suspected of bacteraemia in an outpatient
22
23
24 **7** setting.
25

26
27 **8 Design:** We analysed 315 consecutive HD patients suspected of having bacteraemia with two
28
29
30
31 **9** sets of blood cultures drawn upon admission.
32

33
34 **10 Setting:** Patients were admitted to one of two tertiary-care university medical centres from
35
36
37
38 **11** January 2013 to December 2015.
39

40
41 **12 Participants:** We enrolled consecutive cases on maintenance HD who were aged ≥ 18 years.
42
43
44 **13** Cases of hospitalised patients who had been transferred from another hospital, had a dialysis
45
46
47 **14** vintage < 2 months, were also undergoing peritoneal dialysis (PD), and/or were receiving HD
48
49
50
51 **15** less than once a week were excluded.
52

53
54 **16 Primary and secondary outcome measures:** The primary outcome measure was
55
56
57 **17** bacteraemia and the secondary outcome was in-hospital death.
58
59
60

1
2
3
4 **Results:** Among 315 cases included in the study, 187 had baseline-measured ALP levels. The
5
6
7
8 high-ALP group had a higher incidence of bacteraemia. In multivariate analysis, there was a
9
10
11 statistically significant association between a higher ALP in hospital visit and bacteraemia
12
13
14 (OR: 2.37, 95% CI: 1.17 to 4.83). However, there were no statistically significant
15
16
17 associations between higher ALP and in-hospital death (OR: 1.20, 95% CI: 0.57 to 2.54). A
18
19
20 sensitivity analysis of 187 patients with no missing ALP values also demonstrated a
21
22
23 significant association between elevated ALP and bacteraemia, but no significant association
24
25
26
27 between ALP and in-hospital death.
28

29
30 **Conclusions:** Elevated ALP is a predictor of bacteraemia. In HD patients suspected of
31
32
33 bacteraemia in outpatient settings, increased ALP levels heighten its likelihood.
34
35
36

37 **Trial registration:** none
38
39
40
41
42
43

44 **Strengths and limitations of this study:**

- 45
46
47 14 • This is the first multicentre investigation of the association between ALP levels and
- 48
49
50
51 15 bacteraemia or death in patients on maintenance HD.
- 52
53
54 16 • Elevated serum ALP levels in haemodialysis patients suspected of bacteraemia could lead to
- 55
56
57
58 17 earlier diagnosis and may potentially allow for earlier medical intervention.
59
60

- 1
2
3
4 1 •Our findings should facilitate further research to investigate any causal association of ALP
5
6
7
8 2 elevation with bacteraemia in complex biological systems.
9
10
11 3 •Although the study sample consisted of patients on maintenance HD from two
12
13
14 4 geographically diverse hospitals in Japan, our inferences may not be generalisable to patients
15
16
17 5 on maintenance HD in other clinical settings.
18
19
20
21 6
22
23

24 7 **Keywords:** alkaline phosphatase, bacteraemia, haemodialysis, mortality, prognostic indicator
25
26
27
28 8

30 9 **INTRODUCTION**

31
32
33
34 10 In patients on haemodialysis (HD), it is well known that the second-most common cause of
35
36
37 11 death after cardiovascular events is infection, especially sepsis or bacteraemia[1,2]. The
38
39
40
41 12 prevalence of bacteraemia in patients with HD is 10 to 40 times that in the general
42
43
44 13 population[3,4] with a 50-fold increase in mortality[5–7].
45
46
47

48 14 Multiple studies have shown a positive relationship between serum alkaline
49
50
51 15 phosphatase (ALP) and medium- to long-term mortality in the general population and in
52
53
54 16 chronic kidney disease (CKD) patients, including those on haemodialysis and peritoneal
55
56
57 17 dialysis[8–15]. The explanation is that elevated levels of serum ALP may reflect
58
59
60

1
2
3
4 1 abnormalities such as arterial stiffness, renal osteodystrophy, and inflammation[11,12,16–
5
6
7
8 2 18].
9

10
11 3 In addition to the relationship between serum ALP and mid- to long-term prognosis,
12
13
14 4 observational studies have identified other risk factors for bacteraemia in dialysis patients,
15
16
17 5 including leukocyte dysfunction, malnutrition, parathyroid hormone derangements, and
18
19
20
21 6 vitamin D deficiency[8,19–21].
22
23

24 7 We focused on ALP, an enzyme that hydrolyses phosphate monoester. It is a dimer
25
26
27 8 consisting of two identical molecules, and is expressed as four isoenzymes (placental, germ
28
29
30
31 9 cell, intestinal, and tissue-nonspecific [liver/bone/kidney])[22]. ALP is known as an indicator
32
33
34 10 of renal osteodystrophy, associated with its close relationship with bone, parathyroid gland
35
36
37
38 11 function, the GI tract, and overall mineral balance[23]. Historically, high ALP levels have
39
40
41 12 been considered related to renal osteodystrophy.
42
43

44 13 Damera et al. reported that ALP is one of the inflammatory markers which are
45
46
47 14 independent of 25-OH vitamin D levels in CKD[24]. In addition, the ‘BAC-HD’ (Body
48
49
50
51 15 temperature $\geq 38.3^{\circ}\text{C}$, ALP > 360 U/L, C-reactive protein [CRP] \geq CRP 10 mg/dL, Heart rate
52
53
54 16 ≥ 125 bpm, Drugs: no prior antibiotic use for 1 week) score[25], which we previously
55
56
57
58 17 developed, is a clinical prediction algorithm for bacteraemia among patients with HD.
59
60

1 Tung et al. showed that extremely high ALP levels (ALP > 1000 U/L) were
2 associated with bacteraemia[26]. However, that study had a very small sample size of 16. In
3 other words, there are few studies showing an association between serum ALP and short-term
4 prognosis of bacteraemia and in-hospital mortality.

5 ALP levels can be measured easily and are a less burdensome test for the patient. In
6 addition, bacteraemia is an important outcome for haemodialysis patients because of its high
7 morbidity and mortality. Therefore, it is important to investigate serum ALP levels as
8 predictive markers of bacteraemia. Our aim was to verify the association of ALP levels and
9 bacteraemia or death in maintenance HD patients suspected of bacteraemia in an outpatient
10 setting.

11

12 **METHODS**

13 This study was approved by the ethics committees of Aso Iizuka Hospital (No. 17167),
14 Okinawa Chubu Hospital (H28_No. 51), and Saku Central Hospital (201701-01), and was
15 conducted in accordance with the ethical standards of the Declaration of Helsinki. In the
16 present study, the Department of Nephrology of Aso Iizuka Hospital had collected
17 anonymous data from the participating facilities. Since this study was retrospective, the

1 consent of participants was not obtained. The study results are reported according to the
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 consent of participants was not obtained. The study results are reported according to the
2 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines
3 for cross-sectional studies[27].

5 **Study design and participants**

6 We performed a cross-sectional study at the three academic medical institutions mentioned
7 above. Data were collected from medical records from January 2013 to December 2015 in
8 each facility. We enrolled consecutive cases of patients on maintenance HD who were aged \geq
9 18 years and had had two sets of blood cultures drawn at admission to assess for the presence
10 of bacteraemia. Cases of hospitalised patients who had been transferred from another
11 hospital, had a vintage of dialysis < 2 months, were also undergoing peritoneal dialysis (PD),
12 or were receiving HD less than once a week were excluded (Fig. 1).

14 **ALP levels**

15 Logistic regression analysis was performed with bacteraemia as the dependent variable and
16 ALP as the explanatory variable. Based on the ROC analysis, the value with the highest
17 discriminatory power was used as the cut-off point.

1

2 **Outcomes**

3 The primary outcome was bacteraemia, which was diagnosed based on the results of

4 admission blood cultures. To avoid misclassification of the primary outcome, an external

5 consensus panel of infectious disease physicians with more than ten years' clinical

6 experience and Japanese board certification in infectious disease determined whether a

7 culture was contaminated or not based on the conventional definition of contamination and

8 their clinical expertise. Contamination was defined as: only one of the two sets of culture

9 bottles was positive; or the presence of certain species of bacteria, such as diphtheroids,

10 *Bacillus* spp., *Propionibacterium* spp., *Micrococci* spp., *Corynebacterium* spp., and

11 coagulase-negative staphylococci. The secondary outcome was in-hospital death.

12

13 **Other Covariates**

14 Clinical information collected on hospital admission included age, sex, body temperature,

15 systolic and diastolic blood pressure, pulse rate, respiratory rate, haemodialysis vintage,

16 presence or absence of diabetes mellitus, and use of vitamin D analogues. In addition, white

17 blood cell counts (WBC), aspartate aminotransferase (AST), total bilirubin (T-BIL),

1 corrected calcium (cCa), phosphate (P), and C-reactive protein (CRP) were obtained from
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 corrected calcium (cCa), phosphate (P), and C-reactive protein (CRP) were obtained from
2 medical records.

4 **Statistical analysis**

5 The serum ALP levels at diagnosis were stratified by the cut-off value based on ROC
6 analysis, and patients' baseline characteristics were expressed as medians (quartile) or
7 numbers (%). Multivariate analysis was performed for the primary outcome of bacteraemia in
8 four models adjusted for age, sex, aspartate aminotransferase (AST), vitamin D analogue use,
9 and haemodialysis vintage (Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 +
10 aspartate aminotransferase; Model 3, adjusted for Model 2 + vitamin D analogue use; Model
11 4, adjusted for Model 3 + haemodialysis vintage). Five models were used for the secondary
12 outcome: in-hospital death, adjusted for age, sex, AST, T-BIL, vitamin D analogue use, cCa,
13 P, haemodialysis vintage, and presence of bacteraemia using a logistic regression model
14 (Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase;
15 Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 +
16 haemodialysis vintage; Model 5, adjusted for Model 4 + presence of bacteraemia, Fig. 2). We
17 selected variables for multivariate analysis through a literature review and based on clinical

1 experience. To minimise the bias from missing data, all missing values were imputed using
2 multiple imputation by chained equation (MICE) treated as missing at random including
3 ALP; ten imputed datasets were created[28]. On multivariate analysis, these ten datasets were
4 combined with Rubin's rules and analysed. Analyses were assessed at a two-tailed alpha =
5 0.05. We used commercial software (STATA 15.0, StataCorp LP, College Station, TX, USA)
6 for statistical analysis.

8 **Sample Size**

9 We estimated the prevalence of bacteraemia in maintenance HD patients suspected to have
10 bacteraemia to be 16% based on a previous report[25]. Since we planned a logistic regression
11 analysis with five explanatory variables, we estimated that the number of bacteraemia cases
12 was required to be 50, following the rule of requiring ten outcomes per explanatory
13 variable[29]. From these, it was estimated that a total of 312 subjects was needed.

15 **Sensitivity analysis**

16 To demonstrate the robustness of our inferences, we conducted a complete case analysis for
17 ALP as a sensitivity analysis, which meant excluding participants missing admission ALP.

1 In addition, we added CRP, which is not a confounding factor but is a strong prognostic
 2 factor, and performed a sensitivity analysis.

3 **Patient and public involvement**

4 No current patients or members of the public were directly involved in this study.

5 **RESULTS**

6 The cut-off value for ALP was 360 U/L based on ROC analysis (AUC 0.60, sensitivity 0.49,
 7 specificity 0.76) in complete cases of ALP. Among the 315 cases included in the study
 8 (Figure 1), 187 had baseline measured ALP levels (133 with normal levels \leq 360 U/L and 54
 9 with ALP levels $>$ 360 U/L). Table 1 shows the baseline characteristics of the cohort.

10 **Table 1. Baseline characteristics**

	ALP \leq 360 U/L	ALP $>$ 360 U/L	Total	Missing (N)
	N = 133	N = 54	N = 315	
Age, years, median (IQR)	73 (66, 80)	72 (62, 79)	73 (63, 80)	0
Sex				0
males, n (%)	77 (57.9)	26 (48.1)	178 (56.5)	
females, n (%)	56 (42.1)	28 (51.9)	137 (43.5)	
Diabetes mellitus, n (%)	64 (48.1)	27 (50.0)	159 (50.5)	0
Systolic blood pressure,	134 (110, 150)	134 (11, 150)	134 (110, 150)	2

mmHg, median (IQR)				
Diastolic blood pressure, mmHg, median (IQR)	70 (60, 80)	70 (60, 80)	70 (60, 80)	22
Pulse rate, beats/minute, median (IQR)	90 (78, 102)	92 (84, 108)	90 (78, 102)	4
Respiratory rate, per minute, median (IQR)	20 (18, 24)	20 (18, 24)	20 (18, 24)	43
Body temperature, °C, median (IQR)	37.3 (36.5, 38.0)	37.6 (36.9, 38.3)	37.2 (36.5, 38.0)	6
Laboratory data				
WBC ($\times 10^3/\mu\text{L}$), median (IQR)	8.7 (6.2, 12.4)	8.6 (6.1, 11.3)	8.4 (6.2, 12.0)	2
ALP (U/L), median (IQR)	237 (203, 280)	502 (404, 780)	271 (219, 376)	128
AST (U/L), median (IQR)	17 (12, 25)	24 (18, 55)	18 (13, 25)	7
ALT (U/L), median (IQR)	10 (7, 15)	18 (12, 38)	11 (7.5, 17)	7
T-Bill (mg/dl), median (IQR)	0.5 (0.3, 0.6)	0.6 (0.4, 1.5)	0.5 (0.3, 0.7)	17
Ca (mg/dL), median (IQR)	8.8 (8.4, 9.3)	8.7 (8.3, 9.4)	8.8 (8.4, 9.4)	93
P (mg/dL), median (IQR)	4.4 (3.3, 5.8)	5.3 (4.1, 6.6)	4.7 (3.8, 6.1)	284
CRP (mg/dL), median (IQR)	5.2 (2.1, 11.2)	6.0 (1.5, 12.3)	5.5 (2.1, 12.1)	31
Haemodialysis vintage, months, median (IQR)	51 (17.5, 114)	58 (18, 139)	55 (20, 115)	14
Vitamin D analogue use, n (%)	60 (45.1)	25 (46.3)	134 (42.5)	2
Vascular access				
arteriovenous fistula, n (%)	86 (64.7)	44 (81.5)	130 (41.3)	0
arteriovenous graft, n (%)	11 (8.3)	2 (3.7)	13 (4.1)	0
arteriovenous shunt, n (%)	5 (3.8)	2 (3.7)	7 (2.2)	0
temporary catheter, n (%)	30 (22.6)	6 (11.1)	36 (11.4)	0

1

2 This table shows the baseline characteristics of the cohort.

1
2
3
4 1 Abbreviation: ALP, alkaline phosphatase; WBC, white blood cells; AST, aspartate
5
6
7
8 2 aminotransferase; ALT, alanine aminotransferase; T-Bil, total bilirubin; Ca, calcium; P,
9
10
11 3 phosphorus; CRP, C-reactive protein; IQR Interquartile range
12
13
14
15 4
16
17
18 5 **Occurrence of Outcomes**
19
20
21 6 Table 2 shows the incidence of bacteraemia and in-hospital deaths in the total and groups
22
23
24 7 stratified by ALP. The high-ALP group had a higher incidence of bacteraemia.
25
26
27
28 8
29
30
31 9 **Table 2. Incidence of bacteraemia and in-hospital death in the total and groups**
32
33
34 10 **stratified by ALP**

	ALP \leq 360 U/L N = 133	ALP > 360 U/L N = 54	total N = 315	Missing (N)
Bacteraemia, n (%)	20 (15.0)	19 (35.2)	50 (15.9)	11
In-hospital death, n (%)	17 (12.8)	9 (16.7)	48 (15.2)	22

11
12 This table shows the incidence of bacteraemia and in-hospital deaths in the total and groups
13 stratified by ALP. The high-ALP group had a higher incidence of bacteraemia.

14 Abbreviations: ALP, alkaline phosphatase

1

2 **Association of ALP in hospital visit and bacteraemia**

3 In the multivariate analysis shown in Figure 2, there was a statistically significant association
4 between higher ALP in hospital visit and bacteraemia in all four models.

5

6 **Association of ALP in hospital visit and in-hospital death**

7 As shown in Figure 2, there were no statistically significant associations between higher ALP
8 and in-hospital death in all five models.

9

10 **Sensitivity Analysis**

11 To examine the robustness of the findings, we conducted a complete case analysis for ALP
12 excluding participants who were missing ALP values. A sensitivity analysis of the 187
13 patients with no missing ALP values also demonstrated a significant association between
14 ALP and bacteraemia, but no significant association between ALP and in-hospital death (Fig.
15 2). In a sensitivity analysis with the addition of CRP, results showed no significant
16 association between bacteraemia and ALP levels in analysis adjusted for age, sex, AST, CRP,

1
2
3
4 1 vitamin D analogue use, or haemodialysis vintage (OR: 1.97, 95% CI: 0.97 to 4.01) as shown
5
6
7
8 2 in the Supplementary Figure.
9

10 3 11 12 13 14 4 **DISCUSSION**

15
16
17 5 This study showed a statistically significant positive correlation between ALP levels and
18
19
20
21 6 bacteraemia in HD patients suspected of having bacteraemia in the outpatient setting. Few
22
23
24 7 studies examining the association between serum ALP and short-term prognosis have been
25
26
27 8 reported. This is the first multicentre investigation of the association between ALP levels and
28
29
30
31 9 bacteraemia or death in patients on maintenance HD.
32

33
34 10 Based on the results of this study, elevated serum ALP levels in haemodialysis
35
36
37 11 patients with suspected bacteraemia could allow for early recognition and may potentially
38
39
40
41 12 allow for earlier medical intervention.
42

43 44 13 45 46 47 14 **Association between ALP and bacteraemia**

48
49
50
51 15 We considered two reasons why elevated ALP levels were associated with bacteraemia. First
52
53
54 16 is the involvement of hepatobiliary infections such as cholangitis. We hypothesise that it may
55
56
57 17 cause bacteraemia or sepsis, leading to elevated ALP levels[30,31]. However, since the main
58
59
60

1 cause of bacteraemia in HD patients is bloodstream infection with staphylococci, it is
2 considered that bacteraemia due to biliary tract infection does not significantly affect ALP
3 levels in this population. In addition, we adjusted for the liver enzyme AST in multivariate
4 analysis, but the changes in the OR of bacteraemia were small. These findings suggest that
5 the increase in ALP levels in HD patients was due to factors other than hepatobiliary
6 infection.

7 Second, we considered a biological response to bacteraemia. Previous studies have
8 shown that ALP acts on inflammatory mediators, such as bacterial endotoxin and
9 extracellular adenosine triphosphate, and may detoxify them via
10 dephosphorylation[10,12,32–34]. In animal models of sepsis (mice, rats, sheep, piglets), it has
11 been reported that treatment with ALP reduced systemic inflammation and organ
12 dysfunction, and improved survival[32,35–39]. There are also reports suggesting that ALP is
13 effective in the treatment of sepsis in HD patients[40]. Sepsis-related AKI is thought to be the
14 result of a combination of inflammatory, nephrotoxic, and ischemic injury with rapid
15 progression of renal damage. Pickkers et al. showed that treatment with ALP improved
16 creatinine clearance, as well as the need for and duration of dialysis in patients with sepsis-
17 related AKI[41].

1
2
3
4 1 The above two points suggest that the increase in ALP may be a response to
5
6
7
8 2 inflammation or bacteraemia.
9

10 3 In maintenance haemodialysis patients with a high risk of infection, the therapeutic
11
12
13
14 4 strategy, including antimicrobials, is often distressing until the results of blood culture are
15
16
17
18 5 available. Unnecessary administration of antimicrobials can be harmful to the patient,
19
20
21 6 because antimicrobial resistance is a serious problem for them. However, it has also known
22
23
24 7 that delayed administration of empiric antimicrobial therapy leads to increased mortality.[42]
25
26
27
28 8 We need to decide the timing of administration of therapy and choice of antimicrobial agents
29
30
31 9 appropriately. Serum ALP levels have been reported as one example of a simple clinical
32
33
34 10 prediction rule in the bacteraemia 'BAC-HD score'.[43] In maintenance HD outpatients
35
36
37
38 11 suspected of sepsis, elevated serum ALP levels may indicate the presence of bacteraemia and
39
40
41 12 may aid in the decision to begin early antimicrobial therapy and in the choice of the
42
43
44 13 antimicrobial agent.
45
46
47
48 14

15 **ALP isozymes**

16 Intestinal isozyme may be of possible relevance to sepsis-related treatment.[33, 40] However,
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54 16 Intestinal isozyme may be of possible relevance to sepsis-related treatment.[33, 40] However,
55
56
57 17 no association has been found between specific isozymes and bacteraemia or sepsis, and we
58
59
60

1 do not recommend the measurement of isozymes at this time in clinical practice. If the above
2
3
4
5
6
7
8 two points are resolved, it may be useful to measure ALP isozymes in the future.
9

10

11 3 12 13 14 **The species associated with bacteraemia**

15
16
17
18 5 It is known that percutaneous bloodstream infections caused primarily by gram-positive cocci
19
20
21 6 (GPC) are common in HD patients[44]. However, a previous meta-analysis reported that
22
23
24 7 about 20% of haemodialysis catheter-related bacteraemias were caused by gram-negative
25
26
27
28 8 rods (GNR) as well as coagulase-negative staphylococci and *Staphylococcus aureus*[45].
29

30
31 9 In our study, GNR-induced sepsis accounted for 34% of cases, which may have been
32
33
34 10 associated with ALP levels. However, the median quartile values of ALP in bacteraemia due
35
36
37
38 11 to GPC and GNR were 302 (range, 217, 455) U/L and 388 (range, 225, 530) U/L,
39
40
41 12 respectively, and there may be reasons other than this hypothesis. Second, given the
42
43
44 13 mechanism by which GPC inactivates inflammatory mediators, ALP can be elevated not only
45
46
47
48 14 by GNR but also by GPC-induced sepsis[46]. From the above, it is considered that ALP is
49
50
51 15 associated with bacteraemia in HD patients regardless of the category of the offending
52
53
54 16 bacterium.
55
56
57
58 17
59
60

1 Association between ALP and mortality

2 We found no significant association of ALP with mortality in the analysis for secondary
3 outcome, in contrast to previous studies[10,14,47]. In one study, HD patients with elevated
4 ALP levels had an approximately 50% higher risk of infection-related mortality compared to
5 those with normal ALP levels[14]. One reason for the significant difference in bacteraemia
6 but not in mortality may be that the overall prognosis for maintenance HD patients in Japan is
7 good.

9 Limitations

10 Our study has several limitations. First, there may be unmeasured confounding factors, a
11 limit of observational studies. However, the study was designed to optimise the selection of
12 adjusted confounding factors and to minimise their effect as compared with previous studies.
13 It is possible that intact PTH was a residual confounding factor. However, we could not test
14 this possibility because we did not measure intact PTH in this study, for two reasons: first,
15 because intact PTH may not contribute significantly to outcomes for bacteremia or mortality
16 [48]; and second, since ALP reflects factors of origin other than bone, we considered that the
17 association between PTH and ALP in the acute phase, such as the subject of this study, might

1 be still unclear. Nevertheless, there are reports of increased mortality in patients with PTH
2
3
4 1 be still unclear. Nevertheless, there are reports of increased mortality in patients with PTH
5
6
7
8 2 outside the normal range in the non-acute phase, [49] and further validation is needed.
9
10
11 3 Second, since it is a cross-sectional study, the possibility of reverse causation cannot be
12
13
14 4 denied. However, high ALP levels were shown to be a predictor of bacteraemia. Third, this
15
16
17
18 5 was a retrospective study, and the uncertainty of the data extracted from medical records
19
20
21 6 cannot be ruled out. Fourth, while we conducted a multicentre study, the sample size was
22
23
24 7 relatively small and there were substantial missing data. In patients with ALP data, there was
25
26
27
28 8 a statistically significant association between ALP and bacteraemia, but no association
29
30
31 9 between ALP and in-hospital mortality. We consider the small sample size as a reason why
32
33
34 10 we could not show an association with mortality, unlike previous reports. This is the first
35
36
37
38 11 study suggesting that serum ALP is one of several independent predictors of bacteraemia in
39
40
41 12 HD patients. Our study should facilitate further validation studies to confirm the association
42
43
44 13 of ALP elevation and bacteraemia in maintenance HD patients. Fifth, it cannot be determined
45
46
47
48 14 in this study whether serum ALP levels were elevated before illness or due to bacteraemia.
49
50
51 15 However, baseline serum ALP levels are often unknown in clinical practice. Therefore we
52
53
54 16 consider it may be clinically acceptable. Lastly, the study sample consisted of patients on
55
56
57
58 17 maintenance HD from three geographically diverse hospitals in Japan, and our findings may
59
60

1 not be generalisable to patients on maintenance HD in other clinical settings (e.g., patients
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 not be generalisable to patients on maintenance HD in other clinical settings (e.g., patients
2 with hospitalisation at index dates). Nonetheless, our inferences should remain relevant for
3 over 340,000 patients on maintenance HD in Japan, a vulnerable population with high
4 mortality from bacteraemia, at about 14 times that of the general population [50].
5

6 **CONCLUSIONS**

7 By conducting a multicentre retrospective observational study, we identified elevation of
8 ALP levels as an independent predictor of bacteraemia among maintenance HD outpatients
9 suspected of having sepsis. The association remained consistent after adjusting for other
10 potential predictors for bacteraemia. For clinicians, our data could provide an evidence base
11 for the early identification of patients with bacteraemia and their resultant prompt
12 hospitalisation. Our findings should facilitate further research to investigate any causal
13 association of ALP elevation with bacteraemia in complex biological systems.
14

15 **Contributors:** All authors have read and approved the submission of the manuscript; the
16 manuscript has not been published and is not being considered for publication elsewhere, in
17 whole or in part, in any language, except as an abstract. Sho Sasaki (SS) created the study

1 design. SS, Yoshihiko Raita, Shungo Yamamoto, Kentaro Tochitani, Minoru Murakami, and
2 Ryo Nishioka performed data collection. Aya Katasako and SS analysed data, and wrote the
3 article. All authors reviewed the manuscript. Kiichiro Fujisaki approved the submission of
4 the article.

5 **Competing interests:** All of authors declare that they have no relevant financial interests.

6 **Funding:** None declared.

7 **Data sharing statement:** The data that support the findings of this study are available from
8 the corresponding author upon reasonable request.

9 **Patient consent for publication:** Not required

10 **Ethics statement:** This study was approved by the ethics committees of Aso Iizuka Hospital
11 (No. 17167), Okinawa Chubu Hospital (H28_No. 51), and Saku Central Hospital (201701-
12 01).

13 **Acknowledgment:** We thank Libby Cone, MD, MA, from DMC Corp.
14 (www.dmed.co.jp <<http://www.dmed.co.jp/>>) for editing drafts of this manuscript.

15

1 REFERENCES

1. Pruthi R, Steenkamp R, Feest T. UK Renal Registry 16th annual report: chapter 8 survival and cause of death of UK adult patients on renal replacement therapy in 2012: national and centre-specific analyses. *Nephron Clin Pract* 2013;125:139–69.
2. The Japanese Society for Dialysis Therapy.
<https://docs.jsdt.or.jp/overview/file/2019/pdf/02.pdf>
3. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. *J Am Soc Nephrol* 1998;9:869–876.
4. Dopirak M, Hill C, Oleksiw M, et al. Surveillance of hemodialysis-associated primary bloodstream infections: the experience of ten hospital-based centers. *Infect Control Hosp Epidemiol* 2002;23:721–724.
5. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. *Kidney Int* 2000; 58:1758–1764.
6. Eleftheriadis T, Liakopoulos V, Leivaditis K, Antoniadi G, Stefanidis I. Infections in hemodialysis: a concise review-Part 1: bacteremia and respiratory infections. *Hippokratia* 2011;15:12–17.

- 1
2
3
4 1 7. Foley RN, Guo H, Snyder JJ, Gilbertson DT, Collins AJ. Septicemia in the United
5
6
7
8 2 States dialysis population, 1991 to 1999. *J Am Soc Nephrol* 2004;15:1038–1045.
9
- 10
11 3 8. Rhee CM, Molnar MZ, Lau WL, et al. Comparative mortality-predictability using
12
13
14 4 alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and
15
16
17 5 hemodialysis. *Perit Dial Int* 2014;34:732–748.
18
- 19
20
21 6 9. Owaki A, Inaguma D, Tanaka A, Shinjo H, Inaba S, Kurata K. Evaluation of the
22
23
24 7 relationship between the serum alkaline phosphatase level at dialysis initiation and all-
25
26
27 8 cause mortality: a multicenter, prospective study. *Nephron Extra* 2017;7:78–88.
28
- 29
30
31 9 10. Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts
32
33
34 10 mortality among maintenance hemodialysis patients. *J Am Soc Nephrol*
35
36
37 11 2008;19:2193–2203.
38
- 39
40
41 12 11. Liu X, Guo Q, Feng X, et al. Alkaline phosphatase and mortality in patients on
42
43
44 13 peritoneal dialysis. *Clin J Am Soc Nephrol* 2014;9:771–778.
45
- 46
47
48 14 12. Kovesdy CP, Ureche V, Lu JL, Kalantar-Zadeh K. Outcome predictability of serum
49
50
51 15 alkaline phosphatase in men with pre-dialysis CKD. *Nephrol Dial Transplant*
52
53
54 16 2010;25:3003–3011.
55
56
57
58
59
60

- 1
2
3
4 1 13. Beddhu S, Ma X, Baird B, Cheung AK, Greene T. Serum alkaline phosphatase and
5
6
7
8 2 mortality in African Americans with chronic kidney disease. *Clin J Am Soc Nephrol*
9
10
11 3 2009;4:1805–1810.
12
13
14 4 14. Blayney MJ, Pisoni RL, Bragg-Gresham JL, et al. High alkaline phosphatase levels in
15
16
17 5 hemodialysis patients are associated with higher risk of hospitalization and death.
18
19
20
21 6 *Kidney Int* 2008;74:655–663.
22
23
24 7 15. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-
25
26
27 8 varying indicators of bone disease in maintenance hemodialysis patients. *Kidney Int*
28
29
30
31 9 2006;70:771–780.
32
33
34 10 16. Kerner A, Avizohar O, Sella R, et al. Association between elevated liver enzymes and
35
36
37 11 C-reactive protein: Possible hepatic contribution to systemic inflammation in the
38
39
40
41 12 metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2005;25:193–197.
42
43
44 13 17. Schoppet M, Shanahan CM. Role for alkaline phosphatase as an inducer of vascular
45
46
47 14 calcification in renal failure? *Kidney Int* 2008;73:989–991.
48
49
50
51 15 18. Lomashvili KA, Garg P, Narisawa S, Millán JL, O’Neill WC. Upregulation of alkaline
52
53
54 16 phosphatase and pyrophosphate hydrolysis: Potential mechanism for uremic vascular
55
56
57 17 calcification. *Kidney Int* 2008;73:1024–1030.
58
59
60

- 1
2
3
4 19. Allon M, Depner TA, Radeva M, et al. Impact of dialysis dose and membrane on
5
6
7
8 2 infection-related hospitalization and death: Results of the HEMO Study. *J Am Soc*
9
10
11 3 *Nephrol* 2003;14:1863–1870.
- 12
13
14 20. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in
15
16
17 5 end-stage renal disease: A review. *J Am Soc Nephrol* 1993;3:1541–1554.
- 18
19
20
21 6 21. Su G, Liu Z, Qin X, et al. Vitamin D deficiency and treatment versus risk of infection
22
23
24 7 in end-stage renal disease patients under dialysis: a systematic review and meta-
25
26
27 8 analysis. *Nephrol Dial Transplant* 2019;34:146–156.
- 28
29
30
31 9 22. Millán JL. Alkaline phosphatases: Structure, substrate specificity and functional
32
33
34 10 relatedness to other members of a large superfamily of enzymes. *Purinergic Signal*
35
36
37 11 *2006;2:335–341*.
- 38
39
40
41 12 23. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of
42
43
44 13 renal osteodystrophy: a position statement from *Kidney Disease: Improving Global*
45
46
47 14 *Outcomes (KDIGO)*. *Kidney Int* 2006;69:1945–1953.
- 48
49
50
51 15 24. Damera S, Raphael KL, Baird BC, Cheung AK, Greene T, Beddhu S. Serum alkaline
52
53
54 16 phosphatase levels associate with elevated serum C-reactive protein in chronic kidney
55
56
57 17 disease. *Kidney Int* 2011;79:228–233.
- 58
59
60

- 1
2
3
4 1 25. Sasaki S, Hasegawa T, Kawarazaki H, et al. Development and validation of a clinical
5
6
7
8 2 prediction rule for bacteremia among maintenance hemodialysis patients in outpatient
9
10
11 3 settings. *PLoS One* 2017;12: e0181800.
12
13
14 4 26. Tung CB, Tung CF, Yang DY, et al. Extremely high levels of alkaline phosphatase in
15
16
17 5 adult patients as a manifestation of bacteremia. *Hepatogastroenterology*
18
19
20 6 2005;52:1347–1350.
21
22
23
24 7 27. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP.
25
26
27 8 Strengthening the reporting of observational studies in epidemiology (STROBE)
28
29
30 9 statement: guidelines for reporting observational studies. *BMJ*. 2007;335:806–808.
31
32
33
34 10 28. Janssen KJM, Donders ART, Harrell FE, et al. Missing covariate data in medical
35
36
37 11 research: To impute is better than to ignore. *J Clin Epidemiol* 2010;63:721–727.
38
39
40
41 12 29. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the
42
43
44 13 number of events per variable in logistic regression analysis. *J Clin Epidemiol*
45
46
47 14 1996;49:1373–1379.
48
49
50
51 15 30. Gigot JF, Leese T, Dereme T, Coutinho J, Castaing D, Bismuth H. Acute cholangitis.
52
53
54 16 Multivariate analysis of risk factors. *Ann Surg* 1989;209:435–438.
55
56
57
58
59
60

- 1
2
3
4 1 31. Saharia PC, Cameron JL. Clinical management of acute cholangitis. *Surg Gynecol*
5
6
7
8 2 *Obstet* 1976;142:369–372.
- 9
10
11 3 32. Beumer C, Wulferink M, Raaben W, Fiechter D, Brands R, Seinen W. Calf intestinal
12
13
14 4 alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated
15
16
17 5 diseases, attenuates LPS toxicity in mice and piglets. *J Pharmacol Exp Ther*
18
19
20
21 6 2003;307:737–744.
- 22
23
24 7 33. Lallès JP. Intestinal alkaline phosphatase: multiple biological roles in maintenance of
25
26
27 8 intestinal homeostasis and modulation by diet. *Nutr Rev* 2010;68:323–332.
- 28
29
30
31 9 34. Bates JM, Akerlund J, Mittge E, Guillemin K. Intestinal alkaline phosphatase
32
33
34 10 detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to
35
36
37 11 the gut microbiota. *Cell Host Microbe* 2007;2:371–382.
- 38
39
40
41 12 35. Bentala H, Verweij WR, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Meijer
42
43
44 13 DK, Poelstra K. Removal of phosphate from lipid a as a strategy to detoxify
45
46
47 14 lipopolysaccharide. *Shock* 2002;18:561–566.
- 48
49
50
51 15 36. Koyama I, Matsunaga T, Harada T, Hokari S, Komoda T. Alkaline phosphatases
52
53
54 16 reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation.
55
56
57 17 *Clin Biochem* 2002;35:455–461.
- 58
59
60

- 1
2
3
4 1 37. Verweij WR, Bentala H, Huizinga-Van der Vlag A, et al. Protection against an
5
6
7 2 Escherichia coli-induced sepsis by alkaline phosphatase in mice. *Shock* 2004;22:174–
8
9
10 3 179.
11
12
13
14 4 38. van Veen SQ, van Vliet AK, Wulferink M, Brands R, Boermeester MA, van Gulik
15
16
17 5 TM. Bovine intestinal alkaline phosphatase attenuates the inflammatory response in
18
19
20 6 secondary peritonitis in mice. *Infect Immun* 2005;73:4309–4314.
21
22
23
24 7 39. Su F, Brands R, Wang Z, et al. Beneficial effects of alkaline phosphatase in septic
25
26
27 8 shock. *Crit Care Med* 2006;34:2182–87.
28
29
30
31 9 40. Peters E, Heemskerk S, Masereeuw R, et al. Alkaline phosphatase: A possible
32
33
34 10 treatment for sepsis-associated acute kidney injury in critically ill patients. *Am J*
35
36
37 11 *Kidney Dis* 2014;63:1038–1048.
38
39
40
41 12 41. Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of
42
43
44 13 sepsis-induced acute kidney injury: A prospective randomized double-blind placebo-
45
46
47 14 controlled trial. *Crit Care* 2012;16:R14.
48
49
50
51 15 42. Lee CC, Lee CH, Yang CY, Hsieh CC, Tang HJ, Ko WC. Beneficial effects of early
52
53
54 16 empirical administration of appropriate antimicrobials on survival and defervescence
55
56
57 17 in adults with community-onset bacteremia. *Critical Care* 2019;23:363.
58
59
60

- 1
2
3
4 1 43. Sasaki S, Raita Y, Murakami M, et al. Added value of clinical prediction rules for
5
6
7
8 2 bacteremia in hemodialysis patients: An external validation study. PLoS One
9
10
11 3 2021;16(2):e0247624.
12
13
14 4 44. Vandecasteele SJ, Boelaert JR, De Vriese AS: Staphylococcus aureus infections in
15
16
17 5 hemodialysis: What a nephrologist should know. Clin J Am Soc Nephrol
18
19
20
21 6 2009;4:1388–1400.
22
23
24 7 45. Aslam S, Vaida F, Ritter M, Mehta RL. Systematic review and meta-analysis on
25
26
27 8 management of hemodialysis catheter-related bacteremia. J Am Soc Nephrol
28
29
30
31 9 2014;25:2927–2941.
32
33
34 10 46. Marshall JC, Foster D, Vincent JL, et al. Diagnostic and prognostic implications of
35
36
37 11 endotoxemia in critical illness: results of the MEDIC study. J Infect Dis
38
39
40
41 12 2004;190:527–534.
42
43
44 13 47. Hwang SD, Kim SH, Kim YO, et al. Serum alkaline phosphatase levels predict
45
46
47 14 infection-related mortality and hospitalization in peritoneal dialysis patients. PLoS
48
49
50
51 15 One 2016;11:e0157361.
52
53
54 16 48. Palmer SC, Hayen A, Macaskill P, et al. *JAMA*. 2011;305:1119-27.
55
56
57
58
59
60

- 1
2
3
4 1 49. Hong YA, Kim JH, Kim YK et al. Low parathyroid hormone level predicts infection-
5
6
7 2 related mortality in incident dialysis patients: a prospective cohort study. *Korean J*
8
9
10 3 *Intern Med* 2020;35:160-170.
11
12
13
14 4 50. Wakasugi M, Kawamura K, Yamamoto S, Kazama JJ, Narita I. High mortality rate of
15
16
17 5 infectious diseases in dialysis patients : a comparison with the general population in
18
19
20 6 Japan. *Ther Apher Dial* 2012;16:226–231.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

1

2

3 **Figure 1. Study flow**

4 After the sampling, 315 cases that met the eligibility criteria were included.

5

6 **Figure 2. Association between ALP and bacteraemia or In-hospital death: logistic**

7 **regression model**

8 Multivariate analysis shown in this Figure. There was no relationship between higher ALP
9 and in-hospital death, however there was a statistically significant association between higher
10 ALP and bacteraemia.

11 Bacteraemia outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 +

12 aspartate aminotransferase, Model 3, adjusted for Model 2 + vitamin D analogue use; Model


13 4, adjusted for Model 3 + haemodialysis vintage

14 In-hospital death outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 +

15 aspartate aminotransferase; Model 3, adjusted for Model 2 + vitamin D analogue use; Model

16 4, adjusted for Model 3 + haemodialysis vintage; Model 5, adjusted for Model 4 + presence

17 of bacteraemia



31 Figure 1. Study flow
32 After the sampling, 315 cases that met the eligibility criteria were included.

33 254x190mm (96 x 96 DPI)





Figure 2. Association between ALP and bacteraemia or In-hospital death: logistic regression model Multivariate analysis shown in this Figure. There was no relationship between higher ALP and in-hospital death, however there was a statistically significant association between higher ALP and bacteraemia. Bacteraemia outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase, Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 + haemodialysis vintage In-hospital death outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase; Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 + haemodialysis vintage; Model 5, adjusted for Model 4 + presence of bacteraemia

361x203mm (72 x 72 DPI)

Supplementary Figure: Sensitivity analysis with the addition of CRP



Bacteraemia outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase + CRP; Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 + haemodialysis vintage

In-hospital death outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase + CRP; Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 + haemodialysis vintage; Model 5, adjusted for Model 4 + presence of bacteraemia

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-5
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-11
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10-11
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10-11
		(b) Describe any methods used to examine subgroups and interactions	10-11
		(c) Explain how missing data were addressed	10-11
		(d) If applicable, describe analytical methods taking account of sampling strategy	10-11
		(e) Describe any sensitivity analyses	11
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	12
		(b) Give reasons for non-participation at each stage	12
		(c) Consider use of a flow diagram	12
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12-13
		(b) Indicate number of participants with missing data for each variable of interest	12-13
Outcome data	15*	Report numbers of outcome events or summary measures	13-15
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13-15

		(b) Report category boundaries when continuous variables were categorized	-
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	15
Discussion			
Key results	18	Summarise key results with reference to study objectives	15-16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	20-21
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	16-21
Generalisability	21	Discuss the generalisability (external validity) of the study results	17-18, 20-21
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	22

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

The association between serum alkaline phosphatase and bacteraemia in haemodialysis outpatients: A multicentre retrospective cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058666.R3
Article Type:	Original research
Date Submitted by the Author:	02-Sep-2022
Complete List of Authors:	Katasako, Aya; Iizuka Hospital, Department of Nephrology Sasaki, Sho; Iizuka Hospital, Department of Nephrology; Iizuka Hospital, Clinical Research Support Office Raita, Yoshihiko; Okinawa Chubu Hospital, Department of Nephrology Yamamoto, Shungo; Kyoto University Graduate School of Public Health, Department of Healthcare Epidemiology Tochitani, Kentaro; Kyoto University Graduate School of Public Health, Department of Healthcare Epidemiology Murakami, Minoru; Saku Central Hospital, Department of Nephrology Nishioka, Ryo; Ishikawa Prefectural Central Hospital, Department of Nephrology and Rheumatology Fujisaki, Kiichiro; Iizuka Hospital, Department of Nephrology
Primary Subject Heading:	Medical management
Secondary Subject Heading:	Infectious diseases
Keywords:	INFECTIOUS DISEASES, Dialysis < NEPHROLOGY, Nephrology < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 ORIGINAL ARTICLE
5
6
7

8 **2 The association between serum alkaline phosphatase and bacteraemia in haemodialysis**
9
10 **3 outpatients: A multicentre retrospective cross-sectional study**
11
12
13
14
15
16
17

18 5 Aya Katasako, MD^{1†}, Sho Sasaki, MD, DrPH^{1,2,3,4†}, Yoshihiko Raita, MD, MPH, MMSc⁵,
19
20
21

22 6 Shungo Yamamoto, MD, DrPH⁶, Kentaro Tochitani, MD⁷, Minoru Murakami, MD, MPH⁷,
23
24
25

26 7 Ryo Nishioka, MD⁸, Kiichiro Fujisaki, MD, PhD¹
27
28
29

30
31 9 ¹Department of Nephrology, Iizuka Hospital, Iizuka, Japan, ²Clinical Research Support
32
33

34 10 Office, Iizuka Hospital, Iizuka, Japan, ³Section of Education for Clinical Research, Kyoto
35
36
37

38 11 University Hospital, Kyoto, Japan, ⁴Center for Innovative Research for Communities and
39
40
41

42 12 Clinical Excellence, Fukushima Medical University, Fukushima, JAPAN, ⁵Department of
43
44
45

46 13 Nephrology, Okinawa Chubu Hospital, Uruma, Japan. ⁶Department of Healthcare
47
48
49

50 14 Epidemiology, Kyoto University Graduate School of Public Health, Kyoto, Japan,
51
52
53

54 15 ⁷Department of Nephrology, Saku Central Hospital, Nagano, Japan, ⁸Department of
55
56
57

58 16 Nephrology and Rheumatology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan
59
60

1
2
3
4 1 †These authors contributed equally to this work.
5
6
7

8 2
9

10 3 Correspondence to:
11
12

13
14 4 Sho Sasaki, MD, DrPH
15
16

17 5 Department of Nephrology/Clinical Research Support Office, Iizuka Hospital, Fukuoka,
18
19

20
21 6 JAPAN
22
23

24 7 3-83 Yoshio-machi, Iizuka City, Fukuoka, 820-8505, JAPAN
25
26

27 8 E-mail address: sasaki.sho.3f@kyoto-u.ac.jp
28
29

30 9
31

32 10 Total word count: 3098 words
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **1 ABSTRACT (295 words)**
5

6
7 **2 Objectives:** Elevated baseline serum alkaline phosphatase (ALP) may correlate with higher
8
9
10
11 **3** medium- to long-term mortality in the general population and in chronic kidney disease
12
13
14 **4** (CKD) patients. However, few data are available on the association between serum ALP and
15
16
17
18 **5** the short-term prognosis of patients on haemodialysis (HD). We verified the association of
19
20
21 **6** ALP levels and bacteraemia or death in maintenance HD patients suspected of bacteraemia in
22
23
24 **7** an outpatient setting.
25

26
27 **8 Design:** We analysed 315 consecutive HD patients suspected of having bacteraemia with two
28
29
30
31 **9** sets of blood culture drawn upon admission.
32

33
34 **10 Setting:** Admission to two tertiary-care university medical centres from January 2013 to
35
36
37
38 **11** December 2015.
39

40
41 **12 Participants:** Consecutive cases on maintenance HD aged ≥ 18 years. Cases of hospitalised
42
43
44 **13** patients who had been transferred from another hospital, had a dialysis vintage < 2 months,
45
46
47
48 **14** were also undergoing peritoneal dialysis (PD), and/or were receiving HD less than once a
49
50
51 **15** week were excluded.
52

53
54 **16 Primary and secondary outcome measures:** Primary outcome measure was bacteraemia
55
56
57
58 **17** and secondary outcome was in-hospital death.
59
60

1
2
3
4 1 **Results:** Among 315 cases included in the study, 187 had baseline-measured ALP levels,
5
6
7
8 2 with a cut-off value on ROC analysis of 360 U/L (AUC 0.60, sensitivity 0.49, specificity
9
10
11 3 0.76). In multivariate analysis, there was a statistically significant association between a
12
13
14 4 higher ALP in hospital visit and bacteraemia (OR: 2.37, 95% CI: 1.17 to 4.83). However,
15
16
17
18 5 there were no statistically significant associations between higher ALP and in-hospital death
19
20
21 6 (OR: 1.20, 95% CI: 0.57 to 2.54). A sensitivity analysis of 187 patients with no missing ALP
22
23
24 7 values also demonstrated a significant association between elevated ALP and bacteraemia,
25
26
27
28 8 but no significant association between ALP and in-hospital death.

29
30
31 9 **Conclusions:** Elevated ALP is a predictor of bacteraemia. In HD patients suspected of
32
33
34 10 bacteraemia in outpatient settings, increased ALP levels were associated with increased
35
36
37
38 11 likelihood of confirmed disease.

39
40
41 12 **Trial registration:** none
42
43
44 13

45
46
47
48 14 **Strengths and limitations of this study:**

49
50
51 15 • This is the first multicentre investigation of the association between ALP levels and
52
53
54 16 bacteraemia or death in patients on maintenance HD.
55
56
57
58
59
60

1 •Elevated serum ALP levels in haemodialysis patients suspected of bacteraemia could lead to
2 earlier diagnosis and may potentially allow for earlier medical intervention.

3 •Our findings should facilitate further research to investigate any causal association of ALP
4 elevation with bacteraemia in complex biological systems.

5 •Although the study sample consisted of patients on maintenance HD from two
6 geographically diverse hospitals in Japan, our inferences may not be generalisable to patients
7 on maintenance HD in other clinical settings.

8
9 **Keywords:** alkaline phosphatase, bacteraemia, haemodialysis, mortality, prognostic indicator

10

11 INTRODUCTION

12 In patients on haemodialysis (HD), it is well known that the second-most common cause of
13 death after cardiovascular events is infection, especially sepsis or bacteraemia[1,2]. The
14 prevalence of bacteraemia in patients with HD is 10 to 40 times that in the general
15 population[3,4] with a 50-fold increase in mortality[5–7].

16 Multiple studies have shown a positive relationship between serum alkaline
17 phosphatase (ALP) and medium- to long-term mortality in the general population and in

1
2
3
4 1 chronic kidney disease (CKD) patients, including those on haemodialysis and peritoneal
5
6
7 2 dialysis[8–15]. The explanation is that elevated levels of serum ALP may reflect
8
9
10 3 abnormalities such as arterial stiffness, renal osteodystrophy, and inflammation[11,12,16–
11
12
13
14 4 18].
15
16

17 5 In addition to the relationship between serum ALP and mid- to long-term prognosis,
18
19
20 6 observational studies have identified other risk factors for bacteraemia in dialysis patients,
21
22
23
24 7 including leukocyte dysfunction, malnutrition, parathyroid hormone derangements, and
25
26
27 8 vitamin D deficiency[8,19–21].
28
29

30 9 We focused on ALP, an enzyme that hydrolyses phosphate monoester. It is a dimer
31
32
33 10 consisting of two identical molecules, and is expressed as four isoenzymes (placental, germ
34
35
36
37 11 cell, intestinal, and tissue-nonspecific [liver/bone/kidney])[22]. ALP is known as an indicator
38
39
40
41 12 of renal osteodystrophy, associated with its close relationship with bone, parathyroid gland
42
43
44 13 function, the GI tract, and overall mineral balance[23]. Historically, high ALP levels have
45
46
47
48 14 been considered related to renal osteodystrophy.
49

50 15 Damera et al. reported that ALP is one of the inflammatory markers which are
51
52
53 16 independent of 25-OH vitamin D levels in CKD[24]. In addition, the ‘BAC-HD’ (Body
54
55
56
57 17 temperature $\geq 38.3^{\circ}\text{C}$, ALP > 360 U/L, C-reactive protein [CRP] \geq CRP 10 mg/dL, Heart rate
58
59
60

1 ≥ 125 bpm, Drugs: no prior antibiotic use for 1 week) score[25], which we previously
2 developed, is a clinical prediction algorithm for bacteraemia among patients with HD.

3 Tung et al. showed that extremely high ALP levels (ALP > 1000 U/L) were
4 associated with bacteraemia[26]. However, that study had a very small sample size of 16. In
5 other words, there are few studies showing an association between serum ALP and short-term
6 prognosis of bacteraemia and in-hospital mortality.

7 ALP levels can be measured easily and are a less burdensome test for the patient. In
8 addition, bacteraemia is an important outcome for haemodialysis patients because of its high
9 morbidity and mortality. Therefore, it is important to investigate serum ALP levels as
10 predictive markers of bacteraemia. Our aim was to verify the association of ALP levels and
11 bacteraemia or death in maintenance HD patients suspected of bacteraemia in an outpatient
12 setting.

14 **METHODS**

15 This study was approved by the ethics committees of Aso Iizuka Hospital (No. 17167),
16 Okinawa Chubu Hospital (H28_No. 51), and Saku Central Hospital (201701-01), and was
17 conducted in accordance with the ethical standards of the Declaration of Helsinki. In the

1 present study, the Department of Nephrology of Aso Iizuka Hospital had collected
2 anonymous data from the participating facilities. Since this study was retrospective, the
3 consent of participants was not obtained. The study results are reported according to the
4 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines
5 for cross-sectional studies[27].

7 **Study design and participants**

8 We performed a cross-sectional study at the three academic medical institutions mentioned
9 above. Data were collected from medical records from January 2013 to December 2015 in
10 each facility. We enrolled consecutive cases of patients on maintenance HD who were aged \geq
11 18 years and had had two sets of blood cultures drawn at admission to assess for the presence
12 of bacteraemia. Cases of hospitalised patients who had been transferred from another
13 hospital, had a vintage of dialysis < 2 months, were also undergoing peritoneal dialysis (PD),
14 or were receiving HD less than once a week were excluded (Fig. 1).

16 **ALP levels**

1 Logistic regression analysis was performed with bacteraemia as the dependent variable and
2
3
4
5
6
7
8 2 ALP as the explanatory variable. Based on the ROC analysis, the value with the highest
9
10
11 3 discriminatory power was used as the cut-off point.
12
13
14
15
16
17

18 5 **Outcomes**

19
20
21 6 The primary outcome was bacteraemia, which was diagnosed based on the results of
22
23
24 7 admission blood cultures. To avoid misclassification of the primary outcome, an external
25
26
27
28 8 consensus panel of infectious disease physicians with more than ten years' clinical
29
30
31 9 experience and Japanese board certification in infectious disease determined whether a
32
33
34 10 culture was contaminated or not based on the conventional definition of contamination and
35
36
37
38 11 their clinical expertise. Contamination was defined as: only one of the two sets of culture
39
40
41 12 bottles was positive; or the presence of certain species of bacteria, such as diphtheroids,
42
43
44 13 *Bacillus* spp., *Propionibacterium* spp., *Micrococci* spp., *Corynebacterium* spp., and
45
46
47
48 14 coagulase-negative staphylococci. The secondary outcome was in-hospital death.
49
50
51
52
53

54 16 **Other Covariates**

55
56
57
58
59
60

1
2
3
4 1 Clinical information collected on hospital admission included age, sex, body temperature,
5
6
7 2 systolic and diastolic blood pressure, pulse rate, respiratory rate, haemodialysis vintage,
8
9
10 3 presence or absence of diabetes mellitus, and use of vitamin D analogues. In addition, white
11
12
13
14 4 blood cell counts (WBC), aspartate aminotransferase (AST), total bilirubin (T-BIL),
15
16
17 5 corrected calcium (cCa), phosphate (P), and C-reactive protein (CRP) were obtained from
18
19
20
21 6 medical records.
22
23
24
25
26
27
28
29
30

31 8 **Statistical analysis**

32 9 The serum ALP levels at diagnosis were stratified by the cut-off value based on ROC
33
34 10 analysis, and patients' baseline characteristics were expressed as medians (quartile) or
35
36
37 11 numbers (%). Multivariate analysis was performed for the primary outcome of bacteraemia in
38
39
40
41 12 four models adjusted for age, sex, aspartate aminotransferase (AST), vitamin D analogue use,
42
43
44 13 and haemodialysis vintage (Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 +
45
46
47 14 aspartate aminotransferase; Model 3, adjusted for Model 2 + vitamin D analogue use; Model
48
49
50
51 15 4, adjusted for Model 3 + haemodialysis vintage). Five models were used for the secondary
52
53
54 16 outcome: in-hospital death, adjusted for age, sex, AST, T-BIL, vitamin D analogue use, cCa,
55
56
57
58 17 P, haemodialysis vintage, and presence of bacteraemia using a logistic regression model
59
60

1 (Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase;
2
3
4
5
6
7
8 Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 +
9
10
11 haemodialysis vintage; Model 5, adjusted for Model 4 + presence of bacteraemia, Fig. 2). We
12
13
14 selected variables for multivariate analysis through a literature review and based on clinical
15
16
17
18 experience. To minimise the bias from missing data, all missing values were imputed using
19
20
21
22 multiple imputation by chained equation (MICE) treated as missing at random including
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

10 for statistical analysis.

12 **Sample Size**

13 We estimated the prevalence of bacteraemia in maintenance HD patients suspected to have
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

13 We estimated the prevalence of bacteraemia in maintenance HD patients suspected to have
14 bacteraemia to be 16% based on a previous report[25]. Since we planned a logistic regression
15 analysis with five explanatory variables, we estimated that the number of bacteraemia cases
16 was required to be 50, following the rule of requiring ten outcomes per explanatory
17 variable[29]. From these, it was estimated that a total of 312 subjects was needed.

1
2
3
4 15
6
7
8 **2 Sensitivity analysis**
910
11 3 To demonstrate the robustness of our inferences, we conducted a complete case analysis for12
13
14 4 ALP as a sensitivity analysis, which meant excluding participants missing admission ALP.15
16
17 5 In addition, we added CRP, which is not a confounding factor but is a strong prognostic18
19
20 6 factor, and performed a sensitivity analysis.
21
22
2324 7
25
26
2728 **8 Patient and public involvement**
2930
31 9 No current patients or members of the public were directly involved in this study.
32
3334 10
35
36
3738 **11 RESULTS**
3940
41 12 The cut-off value for ALP was 360 U/L based on ROC analysis (AUC 0.60, sensitivity 0.49,42
43
44 13 specificity 0.76) in complete cases of ALP. Among the 315 cases included in the study45
46
47 14 (Figure 1), 187 had baseline measured ALP levels (133 with normal levels \leq 360 U/L and 5448
49
50 15 with ALP levels $>$ 360 U/L). Table 1 shows the baseline characteristics of the cohort.
51
52
5354 16
55
56
5758 **17 Table 1. Baseline characteristics**
59
60

	ALP ≤ 360 U/L N = 133	ALP > 360 U/L N = 54	Total N = 315	Missing (N)
Age, years, median (IQR)	73 (66, 80)	72 (62, 79)	73 (63, 80)	0
Sex				0
males, n (%)	77 (57.9)	26 (48.1)	178 (56.5)	
females, n (%)	56 (42.1)	28 (51.9)	137 (43.5)	
Diabetes mellitus, n (%)	64 (48.1)	27 (50.0)	159 (50.5)	0
Systolic blood pressure, mmHg, median (IQR)	134 (110, 150)	134 (11, 150)	134 (110, 150)	2
Diastolic blood pressure, mmHg, median (IQR)	70 (60, 80)	70 (60, 80)	70 (60, 80)	22
Pulse rate, beats/minute, median (IQR)	90 (78, 102)	92 (84, 108)	90 (78, 102)	4
Respiratory rate, per minute, median (IQR)	20 (18, 24)	20 (18, 24)	20 (18, 24)	43
Body temperature, °C, median (IQR)	37.3 (36.5, 38.0)	37.6 (36.9, 38.3)	37.2 (36.5, 38.0)	6
Laboratory data				
WBC ($\times 10^3/\mu\text{L}$), median (IQR)	8.7 (6.2, 12.4)	8.6 (6.1, 11.3)	8.4 (6.2, 12.0)	2
ALP (U/L), median (IQR)	237 (203, 280)	502 (404, 780)	271 (219, 376)	128
AST (U/L), median (IQR)	17 (12, 25)	24 (18, 55)	18 (13, 25)	7
ALT (U/L), median (IQR)	10 (7, 15)	18 (12, 38)	11 (7.5, 17)	7
T-Bill (mg/dl), median (IQR)	0.5 (0.3, 0.6)	0.6 (0.4, 1.5)	0.5 (0.3, 0.7)	17
Ca (mg/dL), median (IQR)	8.8 (8.4, 9.3)	8.7 (8.3, 9.4)	8.8 (8.4, 9.4)	93
P (mg/dL), median (IQR)	4.4 (3.3, 5.8)	5.3 (4.1, 6.6)	4.7 (3.8, 6.1)	284
CRP (mg/dL), median (IQR)	5.2 (2.1, 11.2)	6.0 (1.5, 12.3)	5.5 (2.1, 12.1)	31
Haemodialysis vintage, months, median (IQR)	51 (17.5, 114)	58 (18, 139)	55 (20, 115)	14
Vitamin D analogue use, n (%)	60 (45.1)	25 (46.3)	134 (42.5)	2
Vascular access				
arteriovenous fistula, n (%)	86 (64.7)	44 (81.5)	130 (41.3)	0
arteriovenous graft, n (%)	11 (8.3)	2 (3.7)	13 (4.1)	0

arteriovenous shunt, n (%)	5 (3.8)	2 (3.7)	7 (2.2)	0
temporary catheter, n (%)	30 (22.6)	6 (11.1)	36 (11.4)	0

1

2 This table shows the baseline characteristics of the cohort.

3 Abbreviation: ALP, alkaline phosphatase; WBC, white blood cells; AST, aspartate

4 aminotransferase; ALT, alanine aminotransferase; T-Bil, total bilirubin; Ca, calcium; P,

5 phosphorus; CRP, C-reactive protein; IQR Interquartile range

6

7 Occurrence of Outcomes

8 Table 2 shows the incidence of bacteraemia and in-hospital deaths in the total and groups

9 stratified by ALP. The high-ALP group had a higher incidence of bacteraemia.

10

11 Table 2. Incidence of bacteraemia and in-hospital death in the total and groups

12 stratified by ALP

	ALP \leq 360 U/L N = 133	ALP > 360 U/L N = 54	total N = 315	Missing (N)
Bacteraemia, n (%)	20 (15.0)	19 (35.2)	50 (15.9)	11
In-hospital death, n (%)	17 (12.8)	9 (16.7)	48 (15.2)	22

13

1 This table shows the incidence of bacteraemia and in-hospital deaths in the total and groups
2 stratified by ALP. The high-ALP group had a higher incidence of bacteraemia.

3 Abbreviations: ALP, alkaline phosphatase

4

5 **Association of ALP in hospital visit and bacteraemia**

6 In the multivariate analysis shown in Figure 2, there was a statistically significant association
7 between higher ALP in hospital visit and bacteraemia in all four models.

8

9 **Association of ALP in hospital visit and in-hospital death**

10 As shown in Figure 2, there were no statistically significant associations between higher ALP
11 and in-hospital death in all five models.

12

13 **Sensitivity Analysis**

14 To examine the robustness of the findings, we conducted a complete case analysis for ALP
15 excluding participants who were missing ALP values. A sensitivity analysis of the 187
16 patients with no missing ALP values also demonstrated a significant association between
17 ALP and bacteraemia, but no significant association between ALP and in-hospital death (Fig.

1
2
3
4 1 2). In a sensitivity analysis with the addition of CRP, results showed no significant
5
6
7 2 association between bacteraemia and ALP levels in analysis adjusted for age, sex, AST, CRP,
8
9
10 3 vitamin D analogue use, or haemodialysis vintage (OR: 1.97, 95% CI: 0.97 to 4.01) as shown
11
12
13
14 4 in the Supplementary Figure.
15
16
17
18 5
19
20

21 6 **DISCUSSION**

22
23
24 7 This study showed a statistically significant positive correlation between ALP levels and
25
26
27 8 bacteraemia in HD patients suspected of having bacteraemia in the outpatient setting. Few
28
29
30 9 studies examining the association between serum ALP and short-term prognosis have been
31
32
33
34 10 reported. This is the first multicentre investigation of the association between ALP levels and
35
36
37
38 11 bacteraemia or death in patients on maintenance HD.
39
40

41 12 Based on the results of this study, elevated serum ALP levels in haemodialysis
42
43
44 13 patients with suspected bacteraemia could allow for early recognition and may potentially
45
46
47
48 14 allow for earlier medical intervention.
49
50

51 15

52 53 54 16 **Association between ALP and bacteraemia**

55
56
57
58
59
60

1 We considered two reasons why elevated ALP levels were associated with bacteraemia. First
2
3
4
5
6
7
8 2 is the involvement of hepatobiliary infections such as cholangitis. We hypothesise that it may
9
10
11 3 cause bacteraemia or sepsis, leading to elevated ALP levels[30,31]. However, since the main
12
13
14 4 cause of bacteraemia in HD patients is bloodstream infection with staphylococci, it is
15
16
17
18 5 considered that bacteraemia due to biliary tract infection does not significantly affect ALP
19
20
21 6 levels in this population. In addition, we adjusted for the liver enzyme AST in multivariate
22
23
24 7 analysis, but the changes in the OR of bacteraemia were small. These findings suggest that
25
26
27
28 8 the increase in ALP levels in HD patients was due to factors other than hepatobiliary
29
30
31 9 infection.

32
33
34 10 Second, we considered a biological response to bacteraemia. Previous studies have
35
36
37
38 11 shown that ALP acts on inflammatory mediators, such as bacterial endotoxin and
39
40
41 12 extracellular adenosine triphosphate, and may detoxify them via
42
43
44 13 dephosphorylation[10,12,32–34]. In animal models of sepsis (mice, rats, sheep, piglets), it has
45
46
47
48 14 been reported that treatment with ALP reduced systemic inflammation and organ
49
50
51 15 dysfunction, and improved survival[32,35–39]. There are also reports suggesting that ALP is
52
53
54 16 effective in the treatment of sepsis in HD patients[40]. Sepsis-related AKI is thought to be the
55
56
57
58 17 result of a combination of inflammatory, nephrotoxic, and ischemic injury with rapid
59
60

1
2
3
4 1 progression of renal damage. Pickkers et al. showed that treatment with ALP improved
5
6
7 2 creatinine clearance, as well as the need for and duration of dialysis in patients with sepsis-
8
9
10
11 3 related AKI[41].
12
13

14 4 The above two points suggest that the increase in ALP may be a response to
15
16
17 5 inflammation or bacteraemia.
18
19

20
21 6 In maintenance haemodialysis patients with a high risk of infection, the therapeutic
22
23
24 7 strategy, including antimicrobials, is often distressing until the results of blood culture are
25
26
27 8 available. Unnecessary administration of antimicrobials can be harmful to the patient,
28
29
30 9 because antimicrobial resistance is a serious problem for them. However, it has also known
31
32
33
34 10 that delayed administration of empiric antimicrobial therapy leads to increased mortality.[42]
35
36
37
38 11 We need to decide the timing of administration of therapy and choice of antimicrobial agents
39
40
41 12 appropriately. Serum ALP levels have been reported as one example of a simple clinical
42
43
44 13 prediction rule in the bacteraemia 'BAC-HD score'.[43] In maintenance HD outpatients
45
46
47 14 suspected of sepsis, elevated serum ALP levels may indicate the presence of bacteraemia and
48
49
50
51 15 may aid in the decision to begin early antimicrobial therapy and in the choice of the
52
53
54 16 antimicrobial agent.
55
56
57
58 17
59
60

1 **ALP isozymes**

2
3
4
5
6
7
8 2 Intestinal isozyme may be of possible relevance to sepsis-related treatment.[33, 40] However,
9
10
11 3 no association has been found between specific isozymes and bacteraemia or sepsis, and we
12
13
14 4 do not recommend the measurement of isozymes at this time in clinical practice. If the above
15
16
17 5 two points are resolved, it may be useful to measure ALP isozymes in the future.
18
19
20
21
22
23

24 **The species associated with bacteraemia**

25
26
27 8 It is known that percutaneous bloodstream infections caused primarily by gram-positive cocci
28
29
30 9 (GPC) are common in HD patients[44]. However, a previous meta-analysis reported that
31
32
33
34 10 about 20% of haemodialysis catheter-related bacteraemias were caused by gram-negative
35
36
37 11 rods (GNR) as well as coagulase-negative staphylococci and *Staphylococcus aureus*[45].
38
39
40

41 12 In our study, GNR-induced sepsis accounted for 34% of cases, which may have been
42
43
44 13 associated with ALP levels. However, the median quartile values of ALP in bacteraemia due
45
46
47 14 to GPC and GNR were 302 (range, 217, 455) U/L and 388 (range, 225, 530) U/L,
48
49
50
51 15 respectively, and there may be reasons other than this hypothesis. Second, given the
52
53
54 16 mechanism by which GPC inactivates inflammatory mediators, ALP can be elevated not only
55
56
57 17 by GNR but also by GPC-induced sepsis[46]. From the above, it is considered that ALP is
58
59
60

1
2
3
4 1 associated with bacteraemia in HD patients regardless of the category of the offending
5
6
7 2 bacterium.
8
9

10
11 3

14 4 **Association between ALP and mortality**

17 5 We found no significant association of ALP with mortality in the analysis for secondary
18
19
20
21 6 outcome, in contrast to previous studies[10,14,47]. In one study, HD patients with elevated
22
23
24 7 ALP levels had an approximately 50% higher risk of infection-related mortality compared to
25
26
27 8 those with normal ALP levels[14]. One reason for the significant difference in bacteraemia
28
29
30 9 but not in mortality may be that the overall prognosis for maintenance HD patients in Japan is
31
32
33
34 10 good.
35
36

37
38 11

41 12 **Limitations**

44 13 Our study has several limitations. First, there may be unmeasured confounding factors, a
45
46
47 14 limit of observational studies. However, the study was designed to optimise the selection of
48
49
50 15 adjusted confounding factors and to minimise their effect as compared with previous studies.
51
52
53
54 16 It is possible that intact PTH was a residual confounding factor. However, we could not test
55
56
57 17 this possibility because we did not measure intact PTH in this study, for two reasons: first,
58
59
60

1 because intact PTH may not contribute significantly to outcomes for bacteremia or mortality
2
3
4 1 because intact PTH may not contribute significantly to outcomes for bacteremia or mortality
5
6
7 2 [48]; and second, since ALP reflects factors of origin other than bone, we considered that the
8
9
10 3 association between PTH and ALP in the acute phase, such as the subject of this study, might
11
12
13
14 4 be still unclear. Nevertheless, there are reports of increased mortality in patients with PTH
15
16
17 5 outside the normal range in the non-acute phase, [49] and further validation is needed.
18
19
20 6 Second, since it is a cross-sectional study, the possibility of reverse causation cannot be
21
22
23
24 7 denied. However, high ALP levels were shown to be a predictor of bacteraemia. Third, this
25
26
27 8 was a retrospective study, and the uncertainty of the data extracted from medical records
28
29
30 9 cannot be ruled out. Fourth, while we conducted a multicentre study, the sample size was
31
32
33
34 10 relatively small and there were substantial missing data. In patients with ALP data, there was
35
36
37 11 a statistically significant association between ALP and bacteraemia, but no association
38
39
40 12 between ALP and in-hospital mortality. We consider the small sample size as a reason why
41
42
43 13 we could not show an association with mortality, unlike previous reports. This is the first
44
45
46 14 study suggesting that serum ALP is one of several independent predictors of bacteraemia in
47
48
49 15 HD patients. Our study should facilitate further validation studies to confirm the association
50
51
52 16 of ALP elevation and bacteraemia in maintenance HD patients. Fifth, it cannot be determined
53
54
55 17 in this study whether serum ALP levels were elevated before illness or due to bacteraemia.
56
57
58
59
60

1
2
3
4 1 However, baseline serum ALP levels are often unknown in clinical practice. Therefore we
5
6
7
8 2 consider it may be clinically acceptable. Lastly, the study sample consisted of patients on
9
10
11 3 maintenance HD from three geographically diverse hospitals in Japan, and our findings may
12
13
14 4 not be generalisable to patients on maintenance HD in other clinical settings (e.g., patients
15
16
17
18 5 with hospitalisation at index dates). Nonetheless, our inferences should remain relevant for
19
20
21 6 over 340,000 patients on maintenance HD in Japan, a vulnerable population with high
22
23
24 7 mortality from bacteraemia, at about 14 times that of the general population [50].
25
26
27
28 8

30 9 **CONCLUSIONS**

31
32
33
34 10 By conducting a multicentre retrospective observational study, we identified elevation of
35
36
37
38 11 ALP levels as an independent predictor of bacteraemia among maintenance HD outpatients
39
40
41 12 suspected of having sepsis. The association remained consistent after adjusting for other
42
43
44 13 potential predictors for bacteraemia. For clinicians, our data may support the early
45
46
47
48 14 identification of patients with bacteraemia and their resultant prompt hospitalisation. Our
49
50
51 15 findings may facilitate further research to investigate any causal association of ALP elevation
52
53
54 16 with bacteraemia in complex biological systems.
55
56
57
58 17

1 **Contributors:** All authors have read and approved the submission of the manuscript; the
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Contributors:** All authors have read and approved the submission of the manuscript; the
2 manuscript has not been published and is not being considered for publication elsewhere, in
3 whole or in part, in any language, except as an abstract. Sho Sasaki (SS) created the study
4 design. SS, Yoshihiko Raita, Shungo Yamamoto, Kentaro Tochitani, Minoru Murakami, and
5 Ryo Nishioka performed data collection. Aya Katasako and SS analysed data, and wrote the
6 article. All authors reviewed the manuscript. Kiichiro Fujisaki approved the submission of
7 the article.

8 **Competing interests:** All of authors declare that they have no relevant financial interests.

9 **Funding:** None declared.

10 **Data sharing statement:** The data that support the findings of this study are available from
11 the corresponding author upon reasonable request.

12 **Patient consent for publication:** Not required

13 **Ethics statement:** This study was approved by the ethics committees of Aso Iizuka Hospital
14 (No. 17167), Okinawa Chubu Hospital (H28_No. 51), and Saku Central Hospital (201701-
15 01).

16 **Acknowledgment:** We thank Libby Cone, MD, MA, from DMC Corp.
17 (www.dmed.co.jp <<http://www.dmed.co.jp/>>) for editing drafts of this manuscript.

1 REFERENCES

1. Pruthi R, Steenkamp R, Feest T. UK Renal Registry 16th annual report: chapter 8 survival and cause of death of UK adult patients on renal replacement therapy in 2012: national and centre-specific analyses. *Nephron Clin Pract* 2013;125:139–69.
2. The Japanese Society for Dialysis Therapy.
<https://docs.jsdt.or.jp/overview/file/2019/pdf/02.pdf>
3. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. *J Am Soc Nephrol* 1998;9:869–876.
4. Dopirak M, Hill C, Oleksiw M, et al. Surveillance of hemodialysis-associated primary bloodstream infections: the experience of ten hospital-based centers. *Infect Control Hosp Epidemiol* 2002;23:721–724.
5. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. *Kidney Int* 2000; 58:1758–1764.
6. Eleftheriadis T, Liakopoulos V, Leivaditis K, Antoniadi G, Stefanidis I. Infections in hemodialysis: a concise review-Part 1: bacteremia and respiratory infections. *Hippokratia* 2011;15:12–17.

- 1
2
3
4 1 7. Foley RN, Guo H, Snyder JJ, Gilbertson DT, Collins AJ. Septicemia in the United
5
6
7
8 2 States dialysis population, 1991 to 1999. *J Am Soc Nephrol* 2004;15:1038–1045.
9
10
11 3 8. Rhee CM, Molnar MZ, Lau WL, et al. Comparative mortality-predictability using
12
13
14 4 alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and
15
16
17 5 hemodialysis. *Perit Dial Int* 2014;34:732–748.
18
19
20
21 6 9. Owaki A, Inaguma D, Tanaka A, Shinjo H, Inaba S, Kurata K. Evaluation of the
22
23
24 7 relationship between the serum alkaline phosphatase level at dialysis initiation and all-
25
26
27 8 cause mortality: a multicenter, prospective study. *Nephron Extra* 2017;7:78–88.
28
29
30
31 9 10. Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts
32
33
34 10 mortality among maintenance hemodialysis patients. *J Am Soc Nephrol*
35
36
37 11 2008;19:2193–2203.
38
39
40
41 12 11. Liu X, Guo Q, Feng X, et al. Alkaline phosphatase and mortality in patients on
42
43
44 13 peritoneal dialysis. *Clin J Am Soc Nephrol* 2014;9:771–778.
45
46
47
48 14 12. Kovesdy CP, Ureche V, Lu JL, Kalantar-Zadeh K. Outcome predictability of serum
49
50
51 15 alkaline phosphatase in men with pre-dialysis CKD. *Nephrol Dial Transplant*
52
53
54 16 2010;25:3003–3011.
55
56
57
58
59
60

- 1
2
3
4 1 13. Beddhu S, Ma X, Baird B, Cheung AK, Greene T. Serum alkaline phosphatase and
5
6
7
8 2 mortality in African Americans with chronic kidney disease. *Clin J Am Soc Nephrol*
9
10
11 3 2009;4:1805–1810.
12
13
14 4 14. Blayney MJ, Pisoni RL, Bragg-Gresham JL, et al. High alkaline phosphatase levels in
15
16
17 5 hemodialysis patients are associated with higher risk of hospitalization and death.
18
19
20
21 6 *Kidney Int* 2008;74:655–663.
22
23
24 7 15. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-
25
26
27 8 varying indicators of bone disease in maintenance hemodialysis patients. *Kidney Int*
28
29
30
31 9 2006;70:771–780.
32
33
34 10 16. Kerner A, Avizohar O, Sella R, et al. Association between elevated liver enzymes and
35
36
37 11 C-reactive protein: Possible hepatic contribution to systemic inflammation in the
38
39
40
41 12 metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2005;25:193–197.
42
43
44 13 17. Schoppet M, Shanahan CM. Role for alkaline phosphatase as an inducer of vascular
45
46
47 14 calcification in renal failure? *Kidney Int* 2008;73:989–991.
48
49
50
51 15 18. Lomashvili KA, Garg P, Narisawa S, Millán JL, O’Neill WC. Upregulation of alkaline
52
53
54 16 phosphatase and pyrophosphate hydrolysis: Potential mechanism for uremic vascular
55
56
57 17 calcification. *Kidney Int* 2008;73:1024–1030.
58
59
60

- 1
2
3
4 19. Allon M, Depner TA, Radeva M, et al. Impact of dialysis dose and membrane on
5
6
7
8 2 infection-related hospitalization and death: Results of the HEMO Study. *J Am Soc*
9
10
11 3 *Nephrol* 2003;14:1863–1870.
- 12
13
14 20. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in
15
16
17 5 end-stage renal disease: A review. *J Am Soc Nephrol* 1993;3:1541–1554.
- 18
19
20
21 6 21. Su G, Liu Z, Qin X, et al. Vitamin D deficiency and treatment versus risk of infection
22
23
24 7 in end-stage renal disease patients under dialysis: a systematic review and meta-
25
26
27 8 analysis. *Nephrol Dial Transplant* 2019;34:146–156.
- 28
29
30
31 9 22. Millán JL. Alkaline phosphatases: Structure, substrate specificity and functional
32
33
34 10 relatedness to other members of a large superfamily of enzymes. *Purinergic Signal*
35
36
37 11 *2006;2:335–341*.
- 38
39
40
41 12 23. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of
42
43
44 13 renal osteodystrophy: a position statement from *Kidney Disease: Improving Global*
45
46
47 14 *Outcomes (KDIGO)*. *Kidney Int* 2006;69:1945–1953.
- 48
49
50
51 15 24. Damera S, Raphael KL, Baird BC, Cheung AK, Greene T, Beddhu S. Serum alkaline
52
53
54 16 phosphatase levels associate with elevated serum C-reactive protein in chronic kidney
55
56
57 17 disease. *Kidney Int* 2011;79:228–233.
- 58
59
60

- 1
2
3
4 1 25. Sasaki S, Hasegawa T, Kawarazaki H, et al. Development and validation of a clinical
5
6
7
8 2 prediction rule for bacteremia among maintenance hemodialysis patients in outpatient
9
10
11 3 settings. *PLoS One* 2017;12: e0181800.
12
13
14 4 26. Tung CB, Tung CF, Yang DY, et al. Extremely high levels of alkaline phosphatase in
15
16
17 5 adult patients as a manifestation of bacteremia. *Hepatogastroenterology*
18
19
20 6 2005;52:1347–1350.
21
22
23
24 7 27. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP.
25
26
27 8 Strengthening the reporting of observational studies in epidemiology (STROBE)
28
29
30 9 statement: guidelines for reporting observational studies. *BMJ*. 2007;335:806–808.
31
32
33
34 10 28. Janssen KJM, Donders ART, Harrell FE, et al. Missing covariate data in medical
35
36
37 11 research: To impute is better than to ignore. *J Clin Epidemiol* 2010;63:721–727.
38
39
40
41 12 29. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the
42
43
44 13 number of events per variable in logistic regression analysis. *J Clin Epidemiol*
45
46
47 14 1996;49:1373–1379.
48
49
50
51 15 30. Gigot JF, Leese T, Dereme T, Coutinho J, Castaing D, Bismuth H. Acute cholangitis.
52
53
54 16 Multivariate analysis of risk factors. *Ann Surg* 1989;209:435–438.
55
56
57
58
59
60

- 1
2
3
4 1 31. Saharia PC, Cameron JL. Clinical management of acute cholangitis. *Surg Gynecol*
5
6
7
8 2 *Obstet* 1976;142:369–372.
- 9
10
11 3 32. Beumer C, Wulferink M, Raaben W, Fiechter D, Brands R, Seinen W. Calf intestinal
12
13
14 4 alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated
15
16
17 5 diseases, attenuates LPS toxicity in mice and piglets. *J Pharmacol Exp Ther*
18
19
20 6 2003;307:737–744.
- 21
22
23
24 7 33. Lallès JP. Intestinal alkaline phosphatase: multiple biological roles in maintenance of
25
26
27 8 intestinal homeostasis and modulation by diet. *Nutr Rev* 2010;68:323–332.
- 28
29
30
31 9 34. Bates JM, Akerlund J, Mittge E, Guillemin K. Intestinal alkaline phosphatase
32
33
34 10 detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to
35
36
37 11 the gut microbiota. *Cell Host Microbe* 2007;2:371–382.
- 38
39
40
41 12 35. Bentala H, Verweij WR, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Meijer
42
43
44 13 DK, Poelstra K. Removal of phosphate from lipid a as a strategy to detoxify
45
46
47 14 lipopolysaccharide. *Shock* 2002;18:561–566.
- 48
49
50
51 15 36. Koyama I, Matsunaga T, Harada T, Hokari S, Komoda T. Alkaline phosphatases
52
53
54 16 reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation.
55
56
57 17 *Clin Biochem* 2002;35:455–461.
- 58
59
60

- 1
2
3
4 1 37. Verweij WR, Bentala H, Huizinga-Van der Vlag A, et al. Protection against an
5
6
7
8 2 Escherichia coli-induced sepsis by alkaline phosphatase in mice. *Shock* 2004;22:174–
9
10
11 3 179.
12
13
14 4 38. van Veen SQ, van Vliet AK, Wulferink M, Brands R, Boermeester MA, van Gulik
15
16
17 5 TM. Bovine intestinal alkaline phosphatase attenuates the inflammatory response in
18
19
20 6 secondary peritonitis in mice. *Infect Immun* 2005;73:4309–4314.
21
22
23
24 7 39. Su F, Brands R, Wang Z, et al. Beneficial effects of alkaline phosphatase in septic
25
26
27 8 shock. *Crit Care Med* 2006;34:2182–87.
28
29
30
31 9 40. Peters E, Heemskerk S, Masereeuw R, et al. Alkaline phosphatase: A possible
32
33
34 10 treatment for sepsis-associated acute kidney injury in critically ill patients. *Am J*
35
36
37 11 *Kidney Dis* 2014;63:1038–1048.
38
39
40
41 12 41. Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of
42
43
44 13 sepsis-induced acute kidney injury: A prospective randomized double-blind placebo-
45
46
47 14 controlled trial. *Crit Care* 2012;16:R14.
48
49
50
51 15 42. Lee CC, Lee CH, Yang CY, Hsieh CC, Tang HJ, Ko WC. Beneficial effects of early
52
53
54 16 empirical administration of appropriate antimicrobials on survival and defervescence
55
56
57 17 in adults with community-onset bacteremia. *Critical Care* 2019;23:363.
58
59
60

- 1
2
3
4 1 43. Sasaki S, Raita Y, Murakami M, et al. Added value of clinical prediction rules for
5
6
7
8 2 bacteremia in hemodialysis patients: An external validation study. PLoS One
9
10
11 3 2021;16(2):e0247624.
12
13
14 4 44. Vandecasteele SJ, Boelaert JR, De Vriese AS: Staphylococcus aureus infections in
15
16
17 5 hemodialysis: What a nephrologist should know. Clin J Am Soc Nephrol
18
19
20
21 6 2009;4:1388–1400.
22
23
24 7 45. Aslam S, Vaida F, Ritter M, Mehta RL. Systematic review and meta-analysis on
25
26
27 8 management of hemodialysis catheter-related bacteremia. J Am Soc Nephrol
28
29
30
31 9 2014;25:2927–2941.
32
33
34 10 46. Marshall JC, Foster D, Vincent JL, et al. Diagnostic and prognostic implications of
35
36
37 11 endotoxemia in critical illness: results of the MEDIC study. J Infect Dis
38
39
40
41 12 2004;190:527–534.
42
43
44 13 47. Hwang SD, Kim SH, Kim YO, et al. Serum alkaline phosphatase levels predict
45
46
47 14 infection-related mortality and hospitalization in peritoneal dialysis patients. PLoS
48
49
50
51 15 One 2016;11:e0157361.
52
53
54 16 48. Palmer SC, Hayen A, Macaskill P, et al. *JAMA*. 2011;305:1119-27.
55
56
57
58
59
60

- 1
2
3
4 1 49. Hong YA, Kim JH, Kim YK et al. Low parathyroid hormone level predicts infection-
5
6
7
8 2 related mortality in incident dialysis patients: a prospective cohort study. *Korean J*
9
10
11 3 *Intern Med* 2020;35:160-170.
12
13
14 4 50. Wakasugi M, Kawamura K, Yamamoto S, Kazama JJ, Narita I. High mortality rate of
15
16
17
18 5 infectious diseases in dialysis patients : a comparison with the general population in
19
20
21 6 Japan. *Ther Apher Dial* 2012;16: 226–231.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

1

2

3 **Figure 1. Study flow**

4 After the sampling, 315 cases that met the eligibility criteria were included.

5

6 **Figure 2. Association between ALP and bacteraemia or In-hospital death: logistic**

7 **regression model**

8 Multivariate analysis shown in this Figure. There was no relationship between higher ALP
9 and in-hospital death, however there was a statistically significant association between higher
10 ALP and bacteraemia.

11 Bacteraemia outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 +

12 aspartate aminotransferase, Model 3, adjusted for Model 2 + vitamin D analogue use; Model

13 4, adjusted for Model 3 + haemodialysis vintage

14 In-hospital death outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 +

15 aspartate aminotransferase; Model 3, adjusted for Model 2 + vitamin D analogue use; Model

16 4, adjusted for Model 3 + haemodialysis vintage; Model 5, adjusted for Model 4 + presence

17 of bacteraemia




Figure 1. Study flow
After the sampling, 315 cases that met the eligibility criteria were included.

254x190mm (96 x 96 DPI)





Figure 2. Association between ALP and bacteraemia or In-hospital death: logistic regression model Multivariate analysis shown in this Figure. There was no relationship between higher ALP and in-hospital death, however there was a statistically significant association between higher ALP and bacteraemia. Bacteraemia outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase, Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 + haemodialysis vintage In-hospital death outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase; Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 + haemodialysis vintage; Model 5, adjusted for Model 4 + presence of bacteraemia

361x203mm (72 x 72 DPI)

Supplementary Figure: Sensitivity analysis with the addition of CRP



Bacteraemia outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase + CRP; Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 + haemodialysis vintage

In-hospital death outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase + CRP; Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 + haemodialysis vintage; Model 5, adjusted for Model 4 + presence of bacteraemia

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-5
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-11
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10-11
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10-11
		(b) Describe any methods used to examine subgroups and interactions	10-11
		(c) Explain how missing data were addressed	10-11
		(d) If applicable, describe analytical methods taking account of sampling strategy	10-11
		(e) Describe any sensitivity analyses	11
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	12
		(b) Give reasons for non-participation at each stage	12
		(c) Consider use of a flow diagram	12
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12-13
		(b) Indicate number of participants with missing data for each variable of interest	12-13
Outcome data	15*	Report numbers of outcome events or summary measures	13-15
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13-15

		(b) Report category boundaries when continuous variables were categorized	-
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	15
Discussion			
Key results	18	Summarise key results with reference to study objectives	15-16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	20-21
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	16-21
Generalisability	21	Discuss the generalisability (external validity) of the study results	17-18, 20-21
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	22

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.